| Category | Name | IntersectionWithQuery | PValue | GenesInTerm | GenesInQuery | GenesInTermInQuery | ID |
|---|---|---|---|---|---|---|---|
| GeneOntologyMolecularFunction | chromatin binding | 1.20e-06 | 739 | 31 | 9 | GO:0003682 | |
| GeneOntologyMolecularFunction | cis-regulatory region sequence-specific DNA binding | 1.72e-06 | 1271 | 31 | 11 | GO:0000987 | |
| GeneOntologyMolecularFunction | RNA polymerase II transcription regulatory region sequence-specific DNA binding | 6.58e-06 | 1459 | 31 | 11 | GO:0000977 | |
| GeneOntologyMolecularFunction | nuclear receptor binding | 9.52e-06 | 187 | 31 | 5 | GO:0016922 | |
| GeneOntologyMolecularFunction | RNA polymerase II cis-regulatory region sequence-specific DNA binding | 1.13e-05 | 1244 | 31 | 10 | GO:0000978 | |
| GeneOntologyMolecularFunction | transcription factor binding | 1.44e-05 | 753 | 31 | 8 | GO:0008134 | |
| GeneOntologyMolecularFunction | RNA polymerase II-specific DNA-binding transcription factor binding | 3.78e-05 | 417 | 31 | 6 | GO:0061629 | |
| GeneOntologyMolecularFunction | nuclear estrogen receptor binding | 7.53e-05 | 53 | 31 | 3 | GO:0030331 | |
| GeneOntologyMolecularFunction | DNA-binding transcription factor binding | 2.36e-04 | 582 | 31 | 6 | GO:0140297 | |
| GeneOntologyMolecularFunction | protein antigen binding | 2.76e-04 | 16 | 31 | 2 | GO:1990405 | |
| GeneOntologyMolecularFunction | intronic transcription regulatory region sequence-specific DNA binding | 3.13e-04 | 17 | 31 | 2 | GO:0001161 | |
| GeneOntologyMolecularFunction | nuclear glucocorticoid receptor binding | 4.36e-04 | 20 | 31 | 2 | GO:0035259 | |
| GeneOntologyMolecularFunction | RNA stem-loop binding | 4.81e-04 | 21 | 31 | 2 | GO:0035613 | |
| GeneOntologyMolecularFunction | nuclear retinoid X receptor binding | 5.78e-04 | 23 | 31 | 2 | GO:0046965 | |
| GeneOntologyMolecularFunction | beta-catenin binding | 8.41e-04 | 120 | 31 | 3 | GO:0008013 | |
| GeneOntologyMolecularFunction | molecular adaptor activity | 8.54e-04 | 1356 | 31 | 8 | GO:0060090 | |
| GeneOntologyMolecularFunction | DNA-binding transcription factor activity, RNA polymerase II-specific | 1.11e-03 | 1412 | 31 | 8 | GO:0000981 | |
| GeneOntologyMolecularFunction | transcription coactivator activity | 1.18e-03 | 303 | 31 | 4 | GO:0003713 | |
| GeneOntologyMolecularFunction | nuclear androgen receptor binding | 1.20e-03 | 33 | 31 | 2 | GO:0050681 | |
| GeneOntologyMolecularFunction | TBP-class protein binding | 1.20e-03 | 33 | 31 | 2 | GO:0017025 | |
| GeneOntologyMolecularFunction | transcription coregulator binding | 1.31e-03 | 140 | 31 | 3 | GO:0001221 | |
| GeneOntologyMolecularFunction | DNA-binding transcription repressor activity, RNA polymerase II-specific | 1.45e-03 | 320 | 31 | 4 | GO:0001227 | |
| GeneOntologyMolecularFunction | DNA-binding transcription repressor activity | 1.55e-03 | 326 | 31 | 4 | GO:0001217 | |
| GeneOntologyMolecularFunction | transcription coregulator activity | 1.61e-03 | 562 | 31 | 5 | GO:0003712 | |
| GeneOntologyMolecularFunction | protein-macromolecule adaptor activity | 1.68e-03 | 1160 | 31 | 7 | GO:0030674 | |
| GeneOntologyMolecularFunction | chromatin DNA binding | 2.17e-03 | 167 | 31 | 3 | GO:0031490 | |
| GeneOntologyMolecularFunction | histone acetyltransferase activity | 2.84e-03 | 51 | 31 | 2 | GO:0004402 | |
| GeneOntologyMolecularFunction | transcription coactivator binding | 3.17e-03 | 54 | 31 | 2 | GO:0001223 | |
| GeneOntologyMolecularFunction | peptide-lysine-N-acetyltransferase activity | 3.29e-03 | 55 | 31 | 2 | GO:0061733 | |
| GeneOntologyMolecularFunction | nuclear retinoic acid receptor binding | 3.29e-03 | 55 | 31 | 2 | GO:0042974 | |
| GeneOntologyMolecularFunction | nuclear receptor activity | 3.90e-03 | 60 | 31 | 2 | GO:0004879 | |
| GeneOntologyMolecularFunction | peptide N-acetyltransferase activity | 3.90e-03 | 60 | 31 | 2 | GO:0034212 | |
| GeneOntologyMolecularFunction | nuclear receptor coactivator activity | 4.03e-03 | 61 | 31 | 2 | GO:0030374 | |
| GeneOntologyMolecularFunction | ligand-activated transcription factor activity | 4.03e-03 | 61 | 31 | 2 | GO:0098531 | |
| GeneOntologyMolecularFunction | Hsp70 protein binding | 4.29e-03 | 63 | 31 | 2 | GO:0030544 | |
| GeneOntologyMolecularFunction | general transcription initiation factor binding | 4.43e-03 | 64 | 31 | 2 | GO:0140296 | |
| GeneOntologyMolecularFunction | basal RNA polymerase II transcription machinery binding | 4.70e-03 | 66 | 31 | 2 | GO:0001099 | |
| GeneOntologyMolecularFunction | basal transcription machinery binding | 4.70e-03 | 66 | 31 | 2 | GO:0001098 | |
| GeneOntologyMolecularFunction | double-stranded RNA binding | 6.51e-03 | 78 | 31 | 2 | GO:0003725 | |
| GeneOntologyMolecularFunction | N-acetyltransferase activity | 6.51e-03 | 78 | 31 | 2 | GO:0008080 | |
| GeneOntologyMolecularFunction | promoter-specific chromatin binding | 7.34e-03 | 83 | 31 | 2 | GO:1990841 | |
| GeneOntologyMolecularFunction | protein dimerization activity | 9.56e-03 | 1205 | 31 | 6 | GO:0046983 | |
| GeneOntologyMolecularFunction | N-acyltransferase activity | 1.09e-02 | 102 | 31 | 2 | GO:0016410 | |
| GeneOntologyMolecularFunction | hormone binding | 1.11e-02 | 103 | 31 | 2 | GO:0042562 | |
| GeneOntologyMolecularFunction | zinc ion binding | 1.13e-02 | 891 | 31 | 5 | GO:0008270 | |
| GeneOntologyMolecularFunction | acetyltransferase activity | 1.13e-02 | 104 | 31 | 2 | GO:0016407 | |
| GeneOntologyMolecularFunction | single-stranded RNA binding | 1.28e-02 | 111 | 31 | 2 | GO:0003727 | |
| GeneOntologyMolecularFunction | ATP-dependent activity, acting on DNA | 1.65e-02 | 127 | 31 | 2 | GO:0008094 | |
| GeneOntologyBiologicalProcess | positive regulation of female receptivity | 1.23e-08 | 4 | 31 | 3 | GO:0045925 | |
| GeneOntologyBiologicalProcess | nuclear receptor-mediated signaling pathway | 1.68e-08 | 202 | 31 | 7 | GO:0141193 | |
| GeneOntologyBiologicalProcess | hormone-mediated signaling pathway | 6.14e-08 | 244 | 31 | 7 | GO:0009755 | |
| GeneOntologyBiologicalProcess | T follicular helper cell differentiation | 1.07e-07 | 7 | 31 | 3 | GO:0061470 | |
| GeneOntologyBiologicalProcess | negative regulation of transcription by RNA polymerase II | NCOA2 BPTF SP2 FOXP1 ZFHX3 THRA SALL1 SCAF8 EP300 ESR1 NOTCH1 | 1.92e-07 | 1053 | 31 | 11 | GO:0000122 |
| GeneOntologyBiologicalProcess | regulation of female receptivity | 2.57e-07 | 9 | 31 | 3 | GO:0045924 | |
| GeneOntologyBiologicalProcess | positive regulation of transcription by RNA polymerase II | NCOA2 NCOA1 SUPT20HL1 BPTF FOXP1 ZFHX3 PRDM10 THRA SALL1 EP300 ESR1 NOTCH1 | 3.55e-07 | 1390 | 31 | 12 | GO:0045944 |
| GeneOntologyBiologicalProcess | female mating behavior | 6.70e-07 | 12 | 31 | 3 | GO:0060180 | |
| GeneOntologyBiologicalProcess | intracellular receptor signaling pathway | 2.23e-06 | 416 | 31 | 7 | GO:0030522 | |
| GeneOntologyBiologicalProcess | T-helper 17 type immune response | 2.49e-06 | 64 | 31 | 4 | GO:0072538 | |
| GeneOntologyBiologicalProcess | negative regulation of DNA-templated transcription | NCOA2 BPTF SP2 FOXP1 ZFHX3 THRA SALL1 SCAF8 EP300 ESR1 NOTCH1 | 3.21e-06 | 1399 | 31 | 11 | GO:0045892 |
| GeneOntologyBiologicalProcess | negative regulation of RNA biosynthetic process | NCOA2 BPTF SP2 FOXP1 ZFHX3 THRA SALL1 SCAF8 EP300 ESR1 NOTCH1 | 3.53e-06 | 1413 | 31 | 11 | GO:1902679 |
| GeneOntologyBiologicalProcess | mRNA metabolic process | 5.43e-06 | 917 | 31 | 9 | GO:0016071 | |
| GeneOntologyBiologicalProcess | cellular response to hormone stimulus | 8.80e-06 | 727 | 31 | 8 | GO:0032870 | |
| GeneOntologyBiologicalProcess | T-helper cell differentiation | 1.06e-05 | 92 | 31 | 4 | GO:0042093 | |
| GeneOntologyBiologicalProcess | CD4-positive, alpha-beta T cell differentiation involved in immune response | 1.16e-05 | 94 | 31 | 4 | GO:0002294 | |
| GeneOntologyBiologicalProcess | alpha-beta T cell differentiation involved in immune response | 1.21e-05 | 95 | 31 | 4 | GO:0002293 | |
| GeneOntologyBiologicalProcess | positive regulation of intracellular signal transduction | 1.24e-05 | 1299 | 31 | 10 | GO:1902533 | |
| GeneOntologyBiologicalProcess | cellular response to Thyroglobulin triiodothyronine | 1.31e-05 | 4 | 31 | 2 | GO:1904017 | |
| GeneOntologyBiologicalProcess | alpha-beta T cell activation involved in immune response | 1.37e-05 | 98 | 31 | 4 | GO:0002287 | |
| GeneOntologyBiologicalProcess | rhythmic process | 1.38e-05 | 360 | 31 | 6 | GO:0048511 | |
| GeneOntologyBiologicalProcess | regulation of T-helper 17 cell differentiation | 1.63e-05 | 33 | 31 | 3 | GO:2000319 | |
| GeneOntologyBiologicalProcess | T cell differentiation involved in immune response | 1.66e-05 | 103 | 31 | 4 | GO:0002292 | |
| GeneOntologyBiologicalProcess | regulation of miRNA metabolic process | 1.66e-05 | 103 | 31 | 4 | GO:2000628 | |
| GeneOntologyBiologicalProcess | CD4-positive, alpha-beta T cell differentiation | 2.94e-05 | 119 | 31 | 4 | GO:0043367 | |
| GeneOntologyBiologicalProcess | miRNA metabolic process | 2.94e-05 | 119 | 31 | 4 | GO:0010586 | |
| GeneOntologyBiologicalProcess | response to Thyroglobulin triiodothyronine | 3.27e-05 | 6 | 31 | 2 | GO:1904016 | |
| GeneOntologyBiologicalProcess | positive regulation of hydrogen peroxide-mediated programmed cell death | 4.57e-05 | 7 | 31 | 2 | GO:1901300 | |
| GeneOntologyBiologicalProcess | lung development | 4.68e-05 | 269 | 31 | 5 | GO:0030324 | |
| GeneOntologyBiologicalProcess | T-helper 17 cell differentiation | 4.77e-05 | 47 | 31 | 3 | GO:0072539 | |
| GeneOntologyBiologicalProcess | regulation of T-helper 17 type immune response | 4.77e-05 | 47 | 31 | 3 | GO:2000316 | |
| GeneOntologyBiologicalProcess | nuclear receptor-mediated steroid hormone signaling pathway | 4.96e-05 | 136 | 31 | 4 | GO:0030518 | |
| GeneOntologyBiologicalProcess | respiratory tube development | 5.02e-05 | 273 | 31 | 5 | GO:0030323 | |
| GeneOntologyBiologicalProcess | regulation of thyroid hormone receptor signaling pathway | 6.09e-05 | 8 | 31 | 2 | GO:0002155 | |
| GeneOntologyBiologicalProcess | mRNA transcription by RNA polymerase II | 6.46e-05 | 52 | 31 | 3 | GO:0042789 | |
| GeneOntologyBiologicalProcess | T cell activation involved in immune response | 6.89e-05 | 148 | 31 | 4 | GO:0002286 | |
| GeneOntologyBiologicalProcess | thyroid hormone receptor signaling pathway | 7.82e-05 | 9 | 31 | 2 | GO:0002154 | |
| GeneOntologyBiologicalProcess | CD4-positive, alpha-beta T cell activation | 7.84e-05 | 153 | 31 | 4 | GO:0035710 | |
| GeneOntologyBiologicalProcess | steroid hormone receptor signaling pathway | 8.24e-05 | 155 | 31 | 4 | GO:0043401 | |
| GeneOntologyBiologicalProcess | respiratory system development | 8.48e-05 | 305 | 31 | 5 | GO:0060541 | |
| GeneOntologyBiologicalProcess | mRNA transcription | 8.51e-05 | 57 | 31 | 3 | GO:0009299 | |
| GeneOntologyBiologicalProcess | mating behavior | 8.51e-05 | 57 | 31 | 3 | GO:0007617 | |
| GeneOntologyBiologicalProcess | regulation of T-helper cell differentiation | 8.51e-05 | 57 | 31 | 3 | GO:0045622 | |
| GeneOntologyBiologicalProcess | alpha-beta T cell differentiation | 8.66e-05 | 157 | 31 | 4 | GO:0046632 | |
| GeneOntologyBiologicalProcess | response to hormone | 1.15e-04 | 1042 | 31 | 8 | GO:0009725 | |
| GeneOntologyBiologicalProcess | nuclear-transcribed mRNA catabolic process, deadenylation-dependent decay | 1.26e-04 | 65 | 31 | 3 | GO:0000288 | |
| GeneOntologyBiologicalProcess | prostate glandular acinus development | 1.43e-04 | 12 | 31 | 2 | GO:0060525 | |
| GeneOntologyBiologicalProcess | connective tissue development | 1.47e-04 | 343 | 31 | 5 | GO:0061448 | |
| GeneOntologyBiologicalProcess | negative regulation of epithelial cell differentiation | 1.51e-04 | 69 | 31 | 3 | GO:0030857 | |
| GeneOntologyBiologicalProcess | regulation of CD4-positive, alpha-beta T cell differentiation | 1.78e-04 | 73 | 31 | 3 | GO:0043370 | |
| GeneOntologyBiologicalProcess | reproductive behavior | 1.85e-04 | 74 | 31 | 3 | GO:0019098 | |
| GeneOntologyBiologicalProcess | positive regulation of adipose tissue development | 1.97e-04 | 14 | 31 | 2 | GO:1904179 | |
| GeneOntologyBiologicalProcess | negative regulation of T-helper 17 cell differentiation | 1.97e-04 | 14 | 31 | 2 | GO:2000320 | |
| GeneOntologyBiologicalProcess | regulation of morphogenesis of an epithelium | 2.01e-04 | 76 | 31 | 3 | GO:1905330 | |
| GeneOntologyBiologicalProcess | negative regulation of T-helper 17 type immune response | 2.27e-04 | 15 | 31 | 2 | GO:2000317 | |
| GeneOntologyBiologicalProcess | response to steroid hormone | 2.40e-04 | 381 | 31 | 5 | GO:0048545 | |
| GeneOntologyBiologicalProcess | regulation of intracellular steroid hormone receptor signaling pathway | 2.99e-04 | 87 | 31 | 3 | GO:0033143 | |
| GeneOntologyBiologicalProcess | developmental growth | 3.32e-04 | 911 | 31 | 7 | GO:0048589 | |
| GeneOntologyBiologicalProcess | skeletal muscle tissue development | 3.33e-04 | 223 | 31 | 4 | GO:0007519 | |
| GeneOntologyBiologicalProcess | alpha-beta T cell activation | 3.56e-04 | 227 | 31 | 4 | GO:0046631 | |
| GeneOntologyBiologicalProcess | regulation of alpha-beta T cell differentiation | 3.64e-04 | 93 | 31 | 3 | GO:0046637 | |
| GeneOntologyBiologicalProcess | regulation of hydrogen peroxide-mediated programmed cell death | 3.68e-04 | 19 | 31 | 2 | GO:1901298 | |
| GeneOntologyBiologicalProcess | ovulation cycle | 3.87e-04 | 95 | 31 | 3 | GO:0042698 | |
| GeneOntologyBiologicalProcess | regulation of cardiac muscle hypertrophy | 4.12e-04 | 97 | 31 | 3 | GO:0010611 | |
| GeneOntologyBiologicalProcess | cellular response to steroid hormone stimulus | 4.33e-04 | 239 | 31 | 4 | GO:0071383 | |
| GeneOntologyBiologicalProcess | skeletal muscle organ development | 4.39e-04 | 240 | 31 | 4 | GO:0060538 | |
| GeneOntologyBiologicalProcess | muscle organ development | 4.45e-04 | 436 | 31 | 5 | GO:0007517 | |
| GeneOntologyBiologicalProcess | regulation of muscle hypertrophy | 4.50e-04 | 100 | 31 | 3 | GO:0014743 | |
| GeneOntologyBiologicalProcess | regulation of CD4-positive, alpha-beta T cell activation | 4.50e-04 | 100 | 31 | 3 | GO:2000514 | |
| GeneOntologyBiologicalProcess | regulation of cardiac muscle tissue growth | 4.50e-04 | 100 | 31 | 3 | GO:0055021 | |
| GeneOntologyBiologicalProcess | regulation of adipose tissue development | 4.51e-04 | 21 | 31 | 2 | GO:1904177 | |
| GeneOntologyBiologicalProcess | locomotor rhythm | 4.96e-04 | 22 | 31 | 2 | GO:0045475 | |
| GeneOntologyBiologicalProcess | hydrogen peroxide-mediated programmed cell death | 4.96e-04 | 22 | 31 | 2 | GO:0010421 | |
| GeneOntologyBiologicalProcess | negative regulation of T-helper cell differentiation | 4.96e-04 | 22 | 31 | 2 | GO:0045623 | |
| GeneOntologyBiologicalProcess | immune system development | 4.97e-04 | 248 | 31 | 4 | GO:0002520 | |
| GeneOntologyBiologicalProcess | lymphocyte activation involved in immune response | 5.20e-04 | 251 | 31 | 4 | GO:0002285 | |
| GeneOntologyBiologicalProcess | P-body assembly | 5.42e-04 | 23 | 31 | 2 | GO:0033962 | |
| GeneOntologyBiologicalProcess | response to ketone | 5.44e-04 | 254 | 31 | 4 | GO:1901654 | |
| GeneOntologyBiologicalProcess | regulation of heart growth | 5.49e-04 | 107 | 31 | 3 | GO:0060420 | |
| GeneOntologyBiologicalProcess | regulation of neuron differentiation | 5.52e-04 | 255 | 31 | 4 | GO:0045664 | |
| GeneOntologyBiologicalProcess | organ growth | 5.60e-04 | 256 | 31 | 4 | GO:0035265 | |
| GeneOntologyBiologicalProcess | programmed cell death in response to reactive oxygen species | 5.91e-04 | 24 | 31 | 2 | GO:0097468 | |
| GeneOntologyBiologicalProcess | negative regulation of CD4-positive, alpha-beta T cell differentiation | 6.95e-04 | 26 | 31 | 2 | GO:0043371 | |
| GeneOntologyBiologicalProcess | positive regulation of programmed cell death | 7.09e-04 | 739 | 31 | 6 | GO:0043068 | |
| GeneOntologyBiologicalProcess | peroxisome proliferator activated receptor signaling pathway | 8.06e-04 | 28 | 31 | 2 | GO:0035357 | |
| GeneOntologyBiologicalProcess | regulation of striated muscle cell differentiation | 8.23e-04 | 123 | 31 | 3 | GO:0051153 | |
| GeneOntologyBiologicalProcess | negative regulation of alpha-beta T cell differentiation | 9.89e-04 | 31 | 31 | 2 | GO:0046639 | |
| GeneOntologyBiologicalProcess | regulation of androgen receptor signaling pathway | 9.89e-04 | 31 | 31 | 2 | GO:0060765 | |
| GeneOntologyBiologicalProcess | developmental growth involved in morphogenesis | 1.00e-03 | 299 | 31 | 4 | GO:0060560 | |
| GeneOntologyBiologicalProcess | embryo development | 1.01e-03 | 1437 | 31 | 8 | GO:0009790 | |
| GeneOntologyBiologicalProcess | nuclear-transcribed mRNA catabolic process | 1.01e-03 | 132 | 31 | 3 | GO:0000956 | |
| GeneOntologyBiologicalProcess | cardiac cell development | 1.01e-03 | 132 | 31 | 3 | GO:0055006 | |
| GeneOntologyBiologicalProcess | regulation of muscle adaptation | 1.03e-03 | 133 | 31 | 3 | GO:0043502 | |
| GeneOntologyBiologicalProcess | regulation of glucose metabolic process | 1.05e-03 | 134 | 31 | 3 | GO:0010906 | |
| GeneOntologyBiologicalProcess | lymph node development | 1.12e-03 | 33 | 31 | 2 | GO:0048535 | |
| GeneOntologyBiologicalProcess | prostate gland epithelium morphogenesis | 1.12e-03 | 33 | 31 | 2 | GO:0060740 | |
| GeneOntologyBiologicalProcess | cardiac muscle tissue growth | 1.15e-03 | 138 | 31 | 3 | GO:0055017 | |
| GeneOntologyBiologicalProcess | response to lipid | 1.17e-03 | 1126 | 31 | 7 | GO:0033993 | |
| GeneOntologyBiologicalProcess | negative regulation of miRNA metabolic process | 1.19e-03 | 34 | 31 | 2 | GO:2000629 | |
| GeneOntologyBiologicalProcess | prostate gland morphogenesis | 1.19e-03 | 34 | 31 | 2 | GO:0060512 | |
| GeneOntologyCellularComponent | chromatin | NCOA2 NCOA1 SUPT20HL1 BPTF SP2 FOXP1 SP4 ZFHX3 PRDM10 THRA SALL1 EP400 EP300 ESR1 | 6.31e-09 | 1480 | 31 | 14 | GO:0000785 |
| GeneOntologyCellularComponent | transcription regulator complex | 1.84e-06 | 596 | 31 | 8 | GO:0005667 | |
| GeneOntologyCellularComponent | histone acetyltransferase complex | 3.61e-04 | 94 | 31 | 3 | GO:0000123 | |
| GeneOntologyCellularComponent | SWI/SNF superfamily-type complex | 3.84e-04 | 96 | 31 | 3 | GO:0070603 | |
| GeneOntologyCellularComponent | P-body | 4.59e-04 | 102 | 31 | 3 | GO:0000932 | |
| GeneOntologyCellularComponent | protein acetyltransferase complex | 4.86e-04 | 104 | 31 | 3 | GO:0031248 | |
| GeneOntologyCellularComponent | acetyltransferase complex | 5.57e-04 | 109 | 31 | 3 | GO:1902493 | |
| GeneOntologyCellularComponent | nuclear protein-containing complex | 6.99e-04 | 1377 | 31 | 8 | GO:0140513 | |
| GeneOntologyCellularComponent | ATPase complex | 9.09e-04 | 129 | 31 | 3 | GO:1904949 | |
| MousePheno | lethality during fetal growth through weaning, incomplete penetrance | 1.13e-05 | 1124 | 30 | 11 | MP:0011112 | |
| MousePheno | abnormal thyroid-stimulating hormone level | 4.66e-05 | 33 | 30 | 3 | MP:0003971 | |
| MousePheno | abnormal response/metabolism to endogenous compounds | 6.83e-05 | 104 | 30 | 4 | MP:0003638 | |
| MousePheno | abnormal rete testis morphology | 1.24e-04 | 8 | 30 | 2 | MP:0006416 | |
| MousePheno | abnormal left-right axis symmetry of the somites | 1.24e-04 | 8 | 30 | 2 | MP:0005224 | |
| MousePheno | chronic liver inflammation | 1.24e-04 | 8 | 30 | 2 | MP:0031301 | |
| MousePheno | abnormal small intestinal villus morphology | 1.94e-04 | 53 | 30 | 3 | MP:0008108 | |
| MousePheno | decreased areal bone mineral density | 1.98e-04 | 10 | 30 | 2 | MP:0013618 | |
| MousePheno | increased circulating triiodothyronine level | 2.42e-04 | 11 | 30 | 2 | MP:0005480 | |
| MousePheno | increased triiodothyronine level | 3.42e-04 | 13 | 30 | 2 | MP:0005474 | |
| MousePheno | abnormal areal bone mineral density | 3.99e-04 | 14 | 30 | 2 | MP:0013614 | |
| MousePheno | increased circulating thyroxine level | 4.59e-04 | 15 | 30 | 2 | MP:0005477 | |
| MousePheno | reduced male mating frequency | 4.59e-04 | 15 | 30 | 2 | MP:0001380 | |
| MousePheno | ventricle myocardium hypoplasia | 4.62e-04 | 71 | 30 | 3 | MP:0010502 | |
| MousePheno | increased thyroxine level | 5.24e-04 | 16 | 30 | 2 | MP:0005470 | |
| MousePheno | small heart | 5.50e-04 | 321 | 30 | 5 | MP:0002188 | |
| MousePheno | abnormal offspring retrieval | 5.94e-04 | 17 | 30 | 2 | MP:0009731 | |
| MousePheno | increased circulating thyroid-stimulating hormone level | 5.94e-04 | 17 | 30 | 2 | MP:0005122 | |
| MousePheno | abnormal pup retrieval | 5.94e-04 | 17 | 30 | 2 | MP:0001384 | |
| MousePheno | chronic inflammation | 6.32e-04 | 79 | 30 | 3 | MP:0002499 | |
| MousePheno | increased amino acid level | 6.32e-04 | 79 | 30 | 3 | MP:0014527 | |
| MousePheno | increased circulating estradiol level | 6.67e-04 | 18 | 30 | 2 | MP:0005182 | |
| MousePheno | increased circulating levels of thyroid hormone | 7.44e-04 | 19 | 30 | 2 | MP:0003350 | |
| MousePheno | increased circulating estrogen level | 7.44e-04 | 19 | 30 | 2 | MP:0003370 | |
| MousePheno | myocardium hypoplasia | 8.09e-04 | 86 | 30 | 3 | MP:0010500 | |
| MousePheno | decreased compact bone area | 8.26e-04 | 20 | 30 | 2 | MP:0010968 | |
| MousePheno | increased thyroid-stimulating hormone level | 8.26e-04 | 20 | 30 | 2 | MP:0005135 | |
| MousePheno | thin ventricle myocardium compact layer | 8.26e-04 | 20 | 30 | 2 | MP:0010556 | |
| MousePheno | abnormal nervous system development | 9.37e-04 | 1257 | 30 | 9 | MP:0003861 | |
| Domain | Nuc_rcpt_coact | 7.45e-08 | 6 | 30 | 3 | IPR009110 | |
| Domain | DUF1518 | 7.48e-06 | 3 | 30 | 2 | PF07469 | |
| Domain | DUF1518 | 7.48e-06 | 3 | 30 | 2 | IPR010011 | |
| Domain | Src1_rcpt_coact | 7.48e-06 | 3 | 30 | 2 | IPR008955 | |
| Domain | Nuclear_rcpt_coactivator | 7.48e-06 | 3 | 30 | 2 | IPR017426 | |
| Domain | DUF1518 | 7.48e-06 | 3 | 30 | 2 | SM01151 | |
| Domain | Nuc_rcpt_coact_Ncoa-typ | 7.48e-06 | 3 | 30 | 2 | IPR014920 | |
| Domain | SRC-1 | 7.48e-06 | 3 | 30 | 2 | IPR014935 | |
| Domain | SRC-1 | 7.48e-06 | 3 | 30 | 2 | PF08832 | |
| Domain | - | 7.48e-06 | 3 | 30 | 2 | 4.10.630.10 | |
| Domain | Nuc_rec_co-act | 7.48e-06 | 3 | 30 | 2 | PF08815 | |
| Domain | Sp1_fam | 1.11e-04 | 10 | 30 | 2 | IPR030450 | |
| Domain | PAS | 7.31e-04 | 25 | 30 | 2 | PF00989 | |
| Domain | PAS_fold | 7.31e-04 | 25 | 30 | 2 | IPR013767 | |
| Domain | Bromodomain_CS | 7.91e-04 | 26 | 30 | 2 | IPR018359 | |
| Domain | PAS | 1.20e-03 | 32 | 30 | 2 | SM00091 | |
| Domain | ZINC_FINGER_C2H2_2 | 1.27e-03 | 775 | 30 | 6 | PS50157 | |
| Domain | ZINC_FINGER_C2H2_1 | 1.28e-03 | 777 | 30 | 6 | PS00028 | |
| Domain | PAS | 1.36e-03 | 34 | 30 | 2 | IPR000014 | |
| Domain | Znf-RING_LisH | 1.36e-03 | 34 | 30 | 2 | IPR027370 | |
| Domain | zf-RING_UBOX | 1.36e-03 | 34 | 30 | 2 | PF13445 | |
| Domain | PAS | 1.36e-03 | 34 | 30 | 2 | PS50112 | |
| Domain | Znf_C2H2-like | 1.45e-03 | 796 | 30 | 6 | IPR015880 | |
| Domain | Znf_C2H2 | 1.54e-03 | 805 | 30 | 6 | IPR007087 | |
| Domain | ZnF_C2H2 | 1.57e-03 | 808 | 30 | 6 | SM00355 | |
| Domain | BROMODOMAIN_1 | 1.60e-03 | 37 | 30 | 2 | PS00633 | |
| Domain | Bromodomain | 1.69e-03 | 38 | 30 | 2 | PF00439 | |
| Domain | - | 1.87e-03 | 40 | 30 | 2 | 4.10.1000.10 | |
| Domain | BROMODOMAIN_2 | 1.97e-03 | 41 | 30 | 2 | PS50014 | |
| Domain | BROMO | 2.06e-03 | 42 | 30 | 2 | SM00297 | |
| Domain | Bromodomain | 2.06e-03 | 42 | 30 | 2 | IPR001487 | |
| Domain | - | 2.06e-03 | 42 | 30 | 2 | 1.20.920.10 | |
| Domain | zf-C4 | 2.47e-03 | 46 | 30 | 2 | PF00105 | |
| Domain | NUCLEAR_REC_DBD_1 | 2.47e-03 | 46 | 30 | 2 | PS00031 | |
| Domain | Znf_hrmn_rcpt | 2.47e-03 | 46 | 30 | 2 | IPR001628 | |
| Domain | Nuclear_hrmn_rcpt | 2.47e-03 | 46 | 30 | 2 | IPR001723 | |
| Domain | ZnF_C4 | 2.47e-03 | 46 | 30 | 2 | SM00399 | |
| Domain | NUCLEAR_REC_DBD_2 | 2.47e-03 | 46 | 30 | 2 | PS51030 | |
| Domain | - | 2.58e-03 | 47 | 30 | 2 | 1.10.565.10 | |
| Domain | ZnF_C3H1 | 2.69e-03 | 48 | 30 | 2 | SM00356 | |
| Domain | HOLI | 2.69e-03 | 48 | 30 | 2 | SM00430 | |
| Domain | Nucl_hrmn_rcpt_lig-bd | 2.69e-03 | 48 | 30 | 2 | IPR000536 | |
| Domain | Hormone_recep | 2.69e-03 | 48 | 30 | 2 | PF00104 | |
| Domain | zf-CCCH | 2.80e-03 | 49 | 30 | 2 | PF00642 | |
| Pathway | KEGG_MEDICUS_REFERENCE_NUCLEAR_INITIATED_ESTROGEN_SIGNALING_PATHWAY | 3.40e-07 | 11 | 19 | 3 | M47503 | |
| Pathway | REACTOME_ESTROGEN_DEPENDENT_GENE_EXPRESSION | 1.33e-06 | 63 | 19 | 4 | MM15613 | |
| Pathway | PID_ERA_GENOMIC_PATHWAY | 1.42e-06 | 64 | 19 | 4 | M200 | |
| Pathway | REACTOME_RORA_ACTIVATES_GENE_EXPRESSION | 1.67e-06 | 18 | 19 | 3 | M26942 | |
| Pathway | PID_SMAD2_3NUCLEAR_PATHWAY | 3.86e-06 | 82 | 19 | 4 | M2 | |
| Pathway | REACTOME_SUMOYLATION | 4.10e-06 | 189 | 19 | 5 | M27214 | |
| Pathway | PID_RETINOIC_ACID_PATHWAY | 8.24e-06 | 30 | 19 | 3 | M207 | |
| Pathway | BIOCARTA_PELP1_PATHWAY | 1.72e-05 | 5 | 19 | 2 | MM1575 | |
| Pathway | KEGG_MEDICUS_VARIANT_ESR1_POSITIVE_TO_NUCLEAR_INITIATED_ESTROGEN_SIGNALING_PATHWAY | 1.72e-05 | 5 | 19 | 2 | M48983 | |
| Pathway | BIOCARTA_PELP1_PATHWAY | 2.57e-05 | 6 | 19 | 2 | M22062 | |
| Pathway | REACTOME_ESR_MEDIATED_SIGNALING | 2.63e-05 | 133 | 19 | 4 | MM15529 | |
| Pathway | REACTOME_SUMOYLATION_OF_TRANSCRIPTION_COFACTORS | 2.65e-05 | 44 | 19 | 3 | M27295 | |
| Pathway | REACTOME_HATS_ACETYLATE_HISTONES | 3.40e-05 | 142 | 19 | 4 | M27233 | |
| Pathway | PID_HES_HEY_PATHWAY | 3.46e-05 | 48 | 19 | 3 | M288 | |
| Pathway | REACTOME_HEME_SIGNALING | 3.68e-05 | 49 | 19 | 3 | M41832 | |
| Pathway | WP_MECHANISMS_ASSOCIATED_WITH_PLURIPOTENCY | 3.90e-05 | 301 | 19 | 5 | MM15983 | |
| Pathway | REACTOME_ESTROGEN_DEPENDENT_GENE_EXPRESSION | 4.11e-05 | 149 | 19 | 4 | M27888 | |
| Pathway | PID_AR_TF_PATHWAY | 4.66e-05 | 53 | 19 | 3 | M151 | |
| Pathway | BIOCARTA_PPARG_PATHWAY | 4.80e-05 | 8 | 19 | 2 | M22058 | |
| Pathway | REACTOME_REGULATION_OF_NFE2L2_GENE_EXPRESSION | 4.80e-05 | 8 | 19 | 2 | M48024 | |
| Pathway | REACTOME_SUMOYLATION | 6.71e-05 | 169 | 19 | 4 | MM14919 | |
| Pathway | REACTOME_RUNX3_REGULATES_NOTCH_SIGNALING | 7.70e-05 | 10 | 19 | 2 | MM15535 | |
| Pathway | PID_HIF1_TFPATHWAY | 9.00e-05 | 66 | 19 | 3 | M255 | |
| Pathway | REACTOME_NFE2L2_REGULATING_TUMORIGENIC_GENES | 9.40e-05 | 11 | 19 | 2 | M48021 | |
| Pathway | REACTOME_CIRCADIAN_CLOCK | 1.07e-04 | 70 | 19 | 3 | M938 | |
| Pathway | REACTOME_SIGNALING_BY_NUCLEAR_RECEPTORS | 1.08e-04 | 191 | 19 | 4 | MM15586 | |
| Pathway | REACTOME_NR1H2_AND_NR1H3_MEDIATED_SIGNALING | 1.33e-04 | 13 | 19 | 2 | MM15622 | |
| Pathway | REACTOME_TRANSCRIPTIONAL_REGULATION_BY_RUNX3 | 1.37e-04 | 76 | 19 | 3 | MM15520 | |
| Pathway | REACTOME_SYNTHESIS_OF_BILE_ACIDS_AND_BILE_SALTS_VIA_27_HYDROXYCHOLESTEROL | 1.55e-04 | 14 | 19 | 2 | M27074 | |
| Pathway | REACTOME_SYNTHESIS_OF_BILE_ACIDS_AND_BILE_SALTS_VIA_27_HYDROXYCHOLESTEROL | 1.55e-04 | 14 | 19 | 2 | MM14748 | |
| Pathway | REACTOME_RUNX3_REGULATES_NOTCH_SIGNALING | 1.55e-04 | 14 | 19 | 2 | M27808 | |
| Pathway | REACTOME_CELLULAR_RESPONSE_TO_CHEMICAL_STRESS | 1.56e-04 | 210 | 19 | 4 | M41836 | |
| Pathway | PID_REG_GR_PATHWAY | 1.72e-04 | 82 | 19 | 3 | M115 | |
| Pathway | PID_ERB_GENOMIC_PATHWAY | 1.79e-04 | 15 | 19 | 2 | M119 | |
| Pathway | REACTOME_TRANSCRIPTIONAL_REGULATION_OF_WHITE_ADIPOCYTE_DIFFERENTIATION | 1.85e-04 | 84 | 19 | 3 | M1008 | |
| Pathway | REACTOME_ESR_MEDIATED_SIGNALING | 1.86e-04 | 220 | 19 | 4 | M27794 | |
| Pathway | REACTOME_REGULATION_OF_GENE_EXPRESSION_IN_LATE_STAGE_BRANCHING_MORPHOGENESIS_PANCREATIC_BUD_PRECURSOR_CELLS | 2.04e-04 | 16 | 19 | 2 | M27121 | |
| Pathway | WP_ANDROGEN_RECEPTOR_SIGNALING | 2.34e-04 | 91 | 19 | 3 | M39700 | |
| Pathway | REACTOME_RECYCLING_OF_BILE_ACIDS_AND_SALTS | 2.60e-04 | 18 | 19 | 2 | M4862 | |
| Pathway | REACTOME_REGULATION_OF_LIPID_METABOLISM_BY_PPARALPHA | 2.60e-04 | 18 | 19 | 2 | MM15034 | |
| Pathway | REACTOME_SIGNALING_BY_NOTCH1 | 2.60e-04 | 18 | 19 | 2 | MM14775 | |
| Pathway | REACTOME_TRANSCRIPTIONAL_REGULATION_BY_RUNX3 | 2.74e-04 | 96 | 19 | 3 | M27784 | |
| Pathway | REACTOME_RECYCLING_OF_BILE_ACIDS_AND_SALTS | 2.90e-04 | 19 | 19 | 2 | MM14612 | |
| Pathway | REACTOME_NOTCH4_INTRACELLULAR_DOMAIN_REGULATES_TRANSCRIPTION | 3.22e-04 | 20 | 19 | 2 | M27881 | |
| Pathway | REACTOME_ADIPOGENESIS | 4.09e-04 | 110 | 19 | 3 | M48259 | |
| Pathway | REACTOME_CHROMATIN_MODIFYING_ENZYMES | 4.18e-04 | 272 | 19 | 4 | M29619 | |
| Pathway | BIOCARTA_HER2_PATHWAY | 4.28e-04 | 23 | 19 | 2 | MM1480 | |
| Pathway | BIOCARTA_HER2_PATHWAY | 4.28e-04 | 23 | 19 | 2 | M18719 | |
| Pathway | REACTOME_SYNTHESIS_OF_BILE_ACIDS_AND_BILE_SALTS_VIA_7ALPHA_HYDROXYCHOLESTEROL | 4.28e-04 | 23 | 19 | 2 | M1926 | |
| Pathway | REACTOME_SYNTHESIS_OF_BILE_ACIDS_AND_BILE_SALTS_VIA_7ALPHA_HYDROXYCHOLESTEROL | 4.28e-04 | 23 | 19 | 2 | MM14741 | |
| Pathway | REACTOME_CELLULAR_RESPONSES_TO_STIMULI | 4.43e-04 | 505 | 19 | 5 | MM15548 | |
| Pathway | BIOCARTA_VDR_PATHWAY | 4.67e-04 | 24 | 19 | 2 | M13404 | |
| Pathway | REACTOME_REGULATION_OF_LIPID_METABOLISM_BY_PPARALPHA | 5.02e-04 | 118 | 19 | 3 | M27316 | |
| Pathway | REACTOME_NOTCH3_INTRACELLULAR_DOMAIN_REGULATES_TRANSCRIPTION | 5.07e-04 | 25 | 19 | 2 | M27880 | |
| Pathway | REACTOME_ENDOGENOUS_STEROLS | 5.07e-04 | 25 | 19 | 2 | M11184 | |
| Pathway | BIOCARTA_CARM_ER_PATHWAY | 5.49e-04 | 26 | 19 | 2 | M2499 | |
| Pathway | PID_RXR_VDR_PATHWAY | 5.49e-04 | 26 | 19 | 2 | M162 | |
| Pathway | REACTOME_TRANSCRIPTIONAL_REGULATION_BY_THE_AP_2_TFAP2_FAMILY_OF_TRANSCRIPTION_FACTORS | 5.49e-04 | 26 | 19 | 2 | MM15502 | |
| Pathway | REACTOME_CELLULAR_RESPONSES_TO_STIMULI | 5.65e-04 | 828 | 19 | 6 | M27827 | |
| Pathway | REACTOME_SIGNALING_BY_NUCLEAR_RECEPTORS | 5.75e-04 | 296 | 19 | 4 | M27869 | |
| Pathway | REACTOME_ENDOGENOUS_STEROLS | 5.92e-04 | 27 | 19 | 2 | MM14844 | |
| Pathway | REACTOME_BMAL1_CLOCK_NPAS2_ACTIVATES_CIRCADIAN_GENE_EXPRESSION | 5.92e-04 | 27 | 19 | 2 | M26943 | |
| Pathway | REACTOME_SUMOYLATION_OF_INTRACELLULAR_RECEPTORS | 6.37e-04 | 28 | 19 | 2 | MM15042 | |
| Pathway | WP_NUCLEAR_RECEPTORS_METAPATHWAY | 7.18e-04 | 314 | 19 | 4 | M39428 | |
| Pathway | REACTOME_SUMOYLATION_OF_INTRACELLULAR_RECEPTORS | 7.32e-04 | 30 | 19 | 2 | M27323 | |
| Pathway | WP_CONSTITUTIVE_ANDROSTANE_RECEPTOR_PATHWAY | 7.82e-04 | 31 | 19 | 2 | M39476 | |
| Pathway | REACTOME_TRANSCRIPTIONAL_REGULATION_OF_PLURIPOTENT_STEM_CELLS | 7.82e-04 | 31 | 19 | 2 | M27393 | |
| Pathway | WP_PREGNANE_X_RECEPTOR_PATHWAY | 8.33e-04 | 32 | 19 | 2 | M39567 | |
| Pathway | WP_ENDODERM_DIFFERENTIATION | 8.79e-04 | 143 | 19 | 3 | M39591 | |
| Pathway | REACTOME_SYNTHESIS_OF_BILE_ACIDS_AND_BILE_SALTS | 8.86e-04 | 33 | 19 | 2 | M5967 | |
| Pathway | REACTOME_SYNTHESIS_OF_BILE_ACIDS_AND_BILE_SALTS | 8.86e-04 | 33 | 19 | 2 | MM14737 | |
| Pathway | WP_BREAST_CANCER_PATHWAY | 1.09e-03 | 154 | 19 | 3 | M39739 | |
| Pathway | REACTOME_NR1H3_NR1H2_REGULATE_GENE_EXPRESSION_LINKED_TO_CHOLESTEROL_TRANSPORT_AND_EFFLUX | 1.11e-03 | 37 | 19 | 2 | M29790 | |
| Pathway | WP_GENETIC_CAUSES_OF_PORTOSINUSOIDAL_VASCULAR_DISEASE | 1.11e-03 | 37 | 19 | 2 | M45513 | |
| Pathway | REACTOME_TRANSCRIPTIONAL_REGULATION_BY_THE_AP_2_TFAP2_FAMILY_OF_TRANSCRIPTION_FACTORS | 1.18e-03 | 38 | 19 | 2 | M27757 | |
| Pathway | WP_NUCLEAR_RECEPTORS | 1.18e-03 | 38 | 19 | 2 | M39657 | |
| Pathway | WP_NUCLEAR_RECEPTORS | 1.18e-03 | 38 | 19 | 2 | MM15865 | |
| Pathway | REACTOME_SIGNALING_BY_NOTCH | 1.24e-03 | 39 | 19 | 2 | MM14604 | |
| Pathway | REACTOME_CELLULAR_RESPONSE_TO_CHEMICAL_STRESS | 1.26e-03 | 162 | 19 | 3 | MM15688 | |
| Pathway | PID_FOXM1_PATHWAY | 1.30e-03 | 40 | 19 | 2 | M176 | |
| Pathway | REACTOME_SUMOYLATION_OF_TRANSCRIPTION_COFACTORS | 1.30e-03 | 40 | 19 | 2 | MM15000 | |
| Pathway | REACTOME_REGULATION_OF_BETA_CELL_DEVELOPMENT | 1.43e-03 | 42 | 19 | 2 | M17541 | |
| Pathway | REACTOME_ACTIVATION_OF_GENE_EXPRESSION_BY_SREBF_SREBP | 1.43e-03 | 42 | 19 | 2 | M27172 | |
| Pathway | REACTOME_BILE_ACID_AND_BILE_SALT_METABOLISM | 1.57e-03 | 44 | 19 | 2 | M499 | |
| Pathway | PID_HNF3A_PATHWAY | 1.57e-03 | 44 | 19 | 2 | M285 | |
| Pathway | WP_ARYL_HYDROCARBON_RECEPTOR_PATHWAY_WP2873 | 1.65e-03 | 45 | 19 | 2 | M39615 | |
| Pathway | REACTOME_BILE_ACID_AND_BILE_SALT_METABOLISM | 1.65e-03 | 45 | 19 | 2 | MM14751 | |
| Pathway | REACTOME_HATS_ACETYLATE_HISTONES | 1.72e-03 | 46 | 19 | 2 | MM14935 | |
| Pathway | WP_ARYL_HYDROCARBON_RECEPTOR_PATHWAY_WP2586 | 1.72e-03 | 46 | 19 | 2 | M39661 | |
| Pathway | KEGG_NOTCH_SIGNALING_PATHWAY | 1.79e-03 | 47 | 19 | 2 | M7946 | |
| Pathway | REACTOME_NR1H2_AND_NR1H3_MEDIATED_SIGNALING | 1.79e-03 | 47 | 19 | 2 | M29777 | |
| Pathway | WP_ENERGY_METABOLISM | 1.87e-03 | 48 | 19 | 2 | M39590 | |
| Pathway | REACTOME_NOTCH1_INTRACELLULAR_DOMAIN_REGULATES_TRANSCRIPTION | 1.87e-03 | 48 | 19 | 2 | M611 | |
| Pathway | REACTOME_NUCLEAR_RECEPTOR_TRANSCRIPTION_PATHWAY | 1.87e-03 | 48 | 19 | 2 | MM14987 | |
| Pathway | REACTOME_SIGNALING_BY_NOTCH3 | 1.95e-03 | 49 | 19 | 2 | M618 | |
| Pathway | REACTOME_CYTOPROTECTION_BY_HMOX1 | 2.19e-03 | 52 | 19 | 2 | MM15684 | |
| Pathway | BIOCARTA_PPARA_PATHWAY | 2.19e-03 | 52 | 19 | 2 | M2404 | |
| Pathway | REACTOME_NUCLEAR_RECEPTOR_TRANSCRIPTION_PATHWAY | 2.28e-03 | 53 | 19 | 2 | M8276 | |
| Pathway | WP_CIRCADIAN_RHYTHM_GENES | 2.34e-03 | 201 | 19 | 3 | M39605 | |
| Pathway | REACTOME_TRANSCRIPTIONAL_ACTIVATION_OF_MITOCHONDRIAL_BIOGENESIS | 2.45e-03 | 55 | 19 | 2 | M27145 | |
| Pubmed | 2.58e-12 | 5 | 31 | 4 | 12714702 | ||
| Pubmed | 7.73e-12 | 6 | 31 | 4 | 16923966 | ||
| Pubmed | 3.67e-10 | 13 | 31 | 4 | 11266503 | ||
| Pubmed | MED25 is distinct from TRAP220/MED1 in cooperating with CBP for retinoid receptor activation. | 5.14e-10 | 14 | 31 | 4 | 17641689 | |
| Pubmed | Interaction network of human early embryonic transcription factors. | 6.40e-10 | 351 | 31 | 8 | 38297188 | |
| Pubmed | 6.41e-10 | 3 | 31 | 3 | 12482985 | ||
| Pubmed | 1.24e-09 | 808 | 31 | 10 | 20412781 | ||
| Pubmed | NCOA2 NCOA1 BPTF SP2 FOXP1 ZFHX3 SALL1 EP400 SCAF8 EP300 ESR1 RC3H1 | 1.51e-09 | 1429 | 31 | 12 | 35140242 | |
| Pubmed | Identification and functional characterization of transcriptional activators in human cells. | 1.72e-09 | 398 | 31 | 8 | 35016035 | |
| Pubmed | 2.56e-09 | 4 | 31 | 3 | 11113179 | ||
| Pubmed | 2.56e-09 | 4 | 31 | 3 | 12403846 | ||
| Pubmed | 2.56e-09 | 4 | 31 | 3 | 11818499 | ||
| Pubmed | 2.56e-09 | 4 | 31 | 3 | 12574227 | ||
| Pubmed | 2.56e-09 | 4 | 31 | 3 | 19095746 | ||
| Pubmed | A simple method to screen ligands of peroxisome proliferator-activated receptor delta. | 2.56e-09 | 4 | 31 | 3 | 16930961 | |
| Pubmed | 2.56e-09 | 4 | 31 | 3 | 11435616 | ||
| Pubmed | 6.40e-09 | 5 | 31 | 3 | 11014206 | ||
| Pubmed | Ligands specify coactivator nuclear receptor (NR) box affinity for estrogen receptor subtypes. | 6.40e-09 | 5 | 31 | 3 | 11376110 | |
| Pubmed | 6.40e-09 | 5 | 31 | 3 | 16645043 | ||
| Pubmed | SRC-1 and GRIP1 coactivate transcription with hepatocyte nuclear factor 4. | 6.40e-09 | 5 | 31 | 3 | 9812974 | |
| Pubmed | 6.40e-09 | 5 | 31 | 3 | 12554772 | ||
| Pubmed | 1.04e-08 | 28 | 31 | 4 | 24880616 | ||
| Pubmed | 1.28e-08 | 6 | 31 | 3 | 12630920 | ||
| Pubmed | 1.28e-08 | 6 | 31 | 3 | 19838210 | ||
| Pubmed | BRCA1-IRIS regulates cyclin D1 expression in breast cancer cells. | 2.24e-08 | 7 | 31 | 3 | 16860316 | |
| Pubmed | The transcriptional co-activator p/CIP binds CBP and mediates nuclear-receptor function. | 2.24e-08 | 7 | 31 | 3 | 9192892 | |
| Pubmed | Temporal formation of distinct thyroid hormone receptor coactivator complexes in HeLa cells. | 2.24e-08 | 7 | 31 | 3 | 11117530 | |
| Pubmed | Chromatin remodelling by the glucocorticoid receptor requires the BRG1 complex. | 2.24e-08 | 7 | 31 | 3 | 9590696 | |
| Pubmed | 2.24e-08 | 7 | 31 | 3 | 12709428 | ||
| Pubmed | 3.58e-08 | 8 | 31 | 3 | 11050077 | ||
| Pubmed | Targeting of SWI/SNF chromatin remodelling complexes to estrogen-responsive genes. | 3.58e-08 | 8 | 31 | 3 | 12145209 | |
| Pubmed | 3.58e-08 | 8 | 31 | 3 | 9774463 | ||
| Pubmed | 3.58e-08 | 8 | 31 | 3 | 12082103 | ||
| Pubmed | 3.58e-08 | 8 | 31 | 3 | 8616895 | ||
| Pubmed | 3.58e-08 | 8 | 31 | 3 | 10490106 | ||
| Pubmed | A census of human transcription factors: function, expression and evolution. | 6.52e-08 | 908 | 31 | 9 | 19274049 | |
| Pubmed | 7.66e-08 | 10 | 31 | 3 | 12738788 | ||
| Pubmed | 7.66e-08 | 10 | 31 | 3 | 17363140 | ||
| Pubmed | 1.05e-07 | 11 | 31 | 3 | 10454579 | ||
| Pubmed | Electrostatic modulation in steroid receptor recruitment of LXXLL and FXXLF motifs. | 1.05e-07 | 11 | 31 | 3 | 12612084 | |
| Pubmed | Modification of ASC1 by UFM1 is crucial for ERα transactivation and breast cancer development. | 1.40e-07 | 12 | 31 | 3 | 25219498 | |
| Pubmed | 1.40e-07 | 12 | 31 | 3 | 15140878 | ||
| Pubmed | Multiplexed molecular interactions of nuclear receptors using fluorescent microspheres. | 2.32e-07 | 14 | 31 | 3 | 11500849 | |
| Pubmed | 2.90e-07 | 15 | 31 | 3 | 10567404 | ||
| Pubmed | 4.32e-07 | 17 | 31 | 3 | 19183483 | ||
| Pubmed | 6.15e-07 | 19 | 31 | 3 | 28424251 | ||
| Pubmed | Proteomic analyses reveal distinct chromatin-associated and soluble transcription factor complexes. | 6.28e-07 | 857 | 31 | 8 | 25609649 | |
| Pubmed | 7.23e-07 | 20 | 31 | 3 | 16957778 | ||
| Pubmed | 7.23e-07 | 20 | 31 | 3 | 11877444 | ||
| Pubmed | 7.69e-07 | 2 | 31 | 2 | 11682626 | ||
| Pubmed | Interaction of steroid receptor coactivators and estrogen receptors in the human placenta. | 7.69e-07 | 2 | 31 | 2 | 26733313 | |
| Pubmed | 7.69e-07 | 2 | 31 | 2 | 10598586 | ||
| Pubmed | SRC-1 and TIF2 control energy balance between white and brown adipose tissues. | 7.69e-07 | 2 | 31 | 2 | 12507421 | |
| Pubmed | 7.69e-07 | 2 | 31 | 2 | 9427757 | ||
| Pubmed | 7.69e-07 | 2 | 31 | 2 | 23810008 | ||
| Pubmed | 7.69e-07 | 2 | 31 | 2 | 29451493 | ||
| Pubmed | Molecular determinants of the estrogen receptor-coactivator interface. | 7.69e-07 | 2 | 31 | 2 | 10207113 | |
| Pubmed | Partially redundant functions of SRC-1 and TIF2 in postnatal survival and male reproduction. | 7.69e-07 | 2 | 31 | 2 | 15070739 | |
| Pubmed | 7.69e-07 | 2 | 31 | 2 | 11897715 | ||
| Pubmed | Distinct steady-state nuclear receptor coregulator complexes exist in vivo. | 7.69e-07 | 2 | 31 | 2 | 9751728 | |
| Pubmed | 7.69e-07 | 2 | 31 | 2 | 25051172 | ||
| Pubmed | 7.69e-07 | 2 | 31 | 2 | 19934375 | ||
| Pubmed | 7.69e-07 | 2 | 31 | 2 | 25148457 | ||
| Pubmed | 7.69e-07 | 2 | 31 | 2 | 20388208 | ||
| Pubmed | Association of polymorphisms in estrogen and thyroid hormone receptors with thyroid cancer risk. | 7.69e-07 | 2 | 31 | 2 | 19519176 | |
| Pubmed | 7.69e-07 | 2 | 31 | 2 | 15161711 | ||
| Pubmed | Detection of ERalpha-SRC-1 interactions using bioluminescent resonance energy transfer. | 7.69e-07 | 2 | 31 | 2 | 19763509 | |
| Pubmed | 7.69e-07 | 2 | 31 | 2 | 11265755 | ||
| Pubmed | 7.69e-07 | 2 | 31 | 2 | 11937504 | ||
| Pubmed | 7.69e-07 | 2 | 31 | 2 | 15231721 | ||
| Pubmed | Structure of human Roquin-2 and its complex with constitutive-decay element RNA. | 7.69e-07 | 2 | 31 | 2 | 26249698 | |
| Pubmed | 7.69e-07 | 2 | 31 | 2 | 21367855 | ||
| Pubmed | 8.44e-07 | 21 | 31 | 3 | 19596656 | ||
| Pubmed | 9.03e-07 | 83 | 31 | 4 | 28794006 | ||
| Pubmed | 9.76e-07 | 22 | 31 | 3 | 11867769 | ||
| Pubmed | BRCA1 regulates acetylation and ubiquitination of estrogen receptor-alpha. | 2.31e-06 | 3 | 31 | 2 | 19887647 | |
| Pubmed | 2.31e-06 | 3 | 31 | 2 | 16914740 | ||
| Pubmed | Estrogen receptor alpha represses transcription of early target genes via p300 and CtBP1. | 2.31e-06 | 3 | 31 | 2 | 19188451 | |
| Pubmed | Absence of the steroid receptor coactivator-3 induces B-cell lymphoma. | 2.31e-06 | 3 | 31 | 2 | 16675958 | |
| Pubmed | 2.31e-06 | 3 | 31 | 2 | 23583642 | ||
| Pubmed | 2.31e-06 | 3 | 31 | 2 | 38720211 | ||
| Pubmed | 2.31e-06 | 3 | 31 | 2 | 19039327 | ||
| Pubmed | Roquin Paralogs Differentially Regulate Functional NKT Cell Subsets. | 2.31e-06 | 3 | 31 | 2 | 28188245 | |
| Pubmed | 2.31e-06 | 3 | 31 | 2 | 12388168 | ||
| Pubmed | 2.31e-06 | 3 | 31 | 2 | 17045797 | ||
| Pubmed | The MN1 oncoprotein synergizes with coactivators RAC3 and p300 in RAR-RXR-mediated transcription. | 2.31e-06 | 3 | 31 | 2 | 12569362 | |
| Pubmed | 2.31e-06 | 3 | 31 | 2 | 18563714 | ||
| Pubmed | Functional interaction of STAT3 transcription factor with the coactivator NcoA/SRC1a. | 2.31e-06 | 3 | 31 | 2 | 11773079 | |
| Pubmed | 2.31e-06 | 3 | 31 | 2 | 33574497 | ||
| Pubmed | Identification of BAF57 mutations in human breast cancer cell lines. | 2.31e-06 | 3 | 31 | 2 | 16538531 | |
| Pubmed | The function of TIF2/GRIP1 in mouse reproduction is distinct from those of SRC-1 and p/CIP. | 2.31e-06 | 3 | 31 | 2 | 12138202 | |
| Pubmed | 2.31e-06 | 3 | 31 | 2 | 12114525 | ||
| Pubmed | p300 acts as a transcriptional coactivator for mammalian Notch-1. | 2.31e-06 | 3 | 31 | 2 | 11604511 | |
| Pubmed | Structural basis for RNA recognition in roquin-mediated post-transcriptional gene regulation. | 2.31e-06 | 3 | 31 | 2 | 25026077 | |
| Pubmed | 2.31e-06 | 3 | 31 | 2 | 15983373 | ||
| Pubmed | 2.31e-06 | 3 | 31 | 2 | 12371907 | ||
| Pubmed | 2.31e-06 | 3 | 31 | 2 | 21035760 | ||
| Pubmed | Thyroid hormone signaling in vivo requires a balance between coactivators and corepressors. | 2.31e-06 | 3 | 31 | 2 | 24550004 | |
| Pubmed | 2.31e-06 | 3 | 31 | 2 | 21059860 | ||
| Pubmed | RORgammat recruits steroid receptor coactivators to ensure thymocyte survival. | 2.31e-06 | 3 | 31 | 2 | 16148126 | |
| Interaction | CRX interactions | 3.50e-09 | 254 | 31 | 8 | int:CRX | |
| Interaction | FEV interactions | 2.03e-08 | 203 | 31 | 7 | int:FEV | |
| Interaction | NR2F1 interactions | 2.66e-08 | 58 | 31 | 5 | int:NR2F1 | |
| Interaction | TLE3 interactions | 7.39e-08 | 376 | 31 | 8 | int:TLE3 | |
| Interaction | MED23 interactions | 1.29e-07 | 266 | 31 | 7 | int:MED23 | |
| Interaction | SOX7 interactions | 1.54e-07 | 82 | 31 | 5 | int:SOX7 | |
| Interaction | HNF4A interactions | 1.62e-07 | 275 | 31 | 7 | int:HNF4A | |
| Interaction | PGR interactions | 1.74e-07 | 84 | 31 | 5 | int:PGR | |
| Interaction | MAZ interactions | 1.96e-07 | 86 | 31 | 5 | int:MAZ | |
| Interaction | EGR2 interactions | 2.11e-07 | 171 | 31 | 6 | int:EGR2 | |
| Interaction | TEAD1 interactions | 2.50e-07 | 176 | 31 | 6 | int:TEAD1 | |
| Interaction | SF1 interactions | 3.20e-07 | 304 | 31 | 7 | int:SF1 | |
| Interaction | KCTD5 interactions | 3.58e-07 | 97 | 31 | 5 | int:KCTD5 | |
| Interaction | HNF1B interactions | 3.93e-07 | 190 | 31 | 6 | int:HNF1B | |
| Interaction | MYOD1 interactions | 4.44e-07 | 194 | 31 | 6 | int:MYOD1 | |
| Interaction | PDIA6 interactions | 5.23e-07 | 327 | 31 | 7 | int:PDIA6 | |
| Interaction | THRA interactions | 7.02e-07 | 111 | 31 | 5 | int:THRA | |
| Interaction | SELENOP interactions | 7.18e-07 | 12 | 31 | 3 | int:SELENOP | |
| Interaction | NCOA3 interactions | 1.03e-06 | 224 | 31 | 6 | int:NCOA3 | |
| Interaction | NCOA2 interactions | 2.29e-06 | 141 | 31 | 5 | int:NCOA2 | |
| Interaction | NCOA6 interactions | 2.63e-06 | 145 | 31 | 5 | int:NCOA6 | |
| Interaction | NCOA1 interactions | 2.72e-06 | 146 | 31 | 5 | int:NCOA1 | |
| Interaction | MTA1 interactions | 3.99e-06 | 283 | 31 | 6 | int:MTA1 | |
| Interaction | KLF15 interactions | 4.59e-06 | 290 | 31 | 6 | int:KLF15 | |
| Interaction | RXRA interactions | 5.57e-06 | 169 | 31 | 5 | int:RXRA | |
| Interaction | SP7 interactions | 6.01e-06 | 304 | 31 | 6 | int:SP7 | |
| Interaction | TLX1 interactions | 6.60e-06 | 175 | 31 | 5 | int:TLX1 | |
| Interaction | ANIB1 interactions | 6.86e-06 | 3 | 31 | 2 | int:ANIB1 | |
| Interaction | XRCC6 interactions | 7.22e-06 | 928 | 31 | 9 | int:XRCC6 | |
| Interaction | SMG7 interactions | 7.91e-06 | 319 | 31 | 6 | int:SMG7 | |
| Interaction | ALG13 interactions | 8.20e-06 | 183 | 31 | 5 | int:ALG13 | |
| Interaction | THRB interactions | 8.87e-06 | 186 | 31 | 5 | int:THRB | |
| Interaction | ZCCHC9 interactions | 8.91e-06 | 86 | 31 | 4 | int:ZCCHC9 | |
| Interaction | GSC interactions | 9.33e-06 | 87 | 31 | 4 | int:GSC | |
| Interaction | GOLGA2 interactions | 1.11e-05 | 733 | 31 | 8 | int:GOLGA2 | |
| Interaction | KLF5 interactions | 1.12e-05 | 195 | 31 | 5 | int:KLF5 | |
| Interaction | C19orf53 interactions | 1.17e-05 | 29 | 31 | 3 | int:C19orf53 | |
| Interaction | PIAS3 interactions | 1.32e-05 | 95 | 31 | 4 | int:PIAS3 | |
| Interaction | NR1H4 interactions | 1.59e-05 | 32 | 31 | 3 | int:NR1H4 | |
| Interaction | PAX6 interactions | 1.73e-05 | 366 | 31 | 6 | int:PAX6 | |
| Interaction | PLRG1 interactions | 1.83e-05 | 216 | 31 | 5 | int:PLRG1 | |
| Interaction | NFIX interactions | 2.32e-05 | 227 | 31 | 5 | int:NFIX | |
| Interaction | KLF3 interactions | 2.37e-05 | 228 | 31 | 5 | int:KLF3 | |
| Interaction | CNOT9 interactions | 2.52e-05 | 231 | 31 | 5 | int:CNOT9 | |
| Interaction | FHL2 interactions | 2.69e-05 | 396 | 31 | 6 | int:FHL2 | |
| Interaction | RORA interactions | 2.90e-05 | 39 | 31 | 3 | int:RORA | |
| Interaction | SP2 interactions | 2.90e-05 | 39 | 31 | 3 | int:SP2 | |
| Interaction | ELK3 interactions | 3.32e-05 | 120 | 31 | 4 | int:ELK3 | |
| Interaction | GATAD2B interactions | 3.35e-05 | 245 | 31 | 5 | int:GATAD2B | |
| Interaction | TFF1 interactions | 3.38e-05 | 41 | 31 | 3 | int:TFF1 | |
| Interaction | NR5A2 interactions | 3.38e-05 | 41 | 31 | 3 | int:NR5A2 | |
| Interaction | ETS1 interactions | 3.43e-05 | 121 | 31 | 4 | int:ETS1 | |
| Interaction | DDX17 interactions | 4.05e-05 | 426 | 31 | 6 | int:DDX17 | |
| Interaction | SNRNP40 interactions | 4.14e-05 | 637 | 31 | 7 | int:SNRNP40 | |
| Interaction | C11orf98 interactions | 4.18e-05 | 44 | 31 | 3 | int:C11orf98 | |
| Interaction | PAX9 interactions | 4.54e-05 | 130 | 31 | 4 | int:PAX9 | |
| Interaction | PTBP1 interactions | 4.67e-05 | 437 | 31 | 6 | int:PTBP1 | |
| Interaction | AHR interactions | 4.82e-05 | 132 | 31 | 4 | int:AHR | |
| Interaction | PYM1 interactions | 4.97e-05 | 133 | 31 | 4 | int:PYM1 | |
| Interaction | KIF11 interactions | 5.04e-05 | 267 | 31 | 5 | int:KIF11 | |
| Interaction | SMAD3 interactions | 5.29e-05 | 447 | 31 | 6 | int:SMAD3 | |
| Interaction | PPP2R1A interactions | 5.44e-05 | 665 | 31 | 7 | int:PPP2R1A | |
| Interaction | NR1I3 interactions | 5.44e-05 | 48 | 31 | 3 | int:NR1I3 | |
| Interaction | NR1I2 interactions | 5.44e-05 | 48 | 31 | 3 | int:NR1I2 | |
| Interaction | PRPF19 interactions | 5.49e-05 | 450 | 31 | 6 | int:PRPF19 | |
| Interaction | RBM27 interactions | 5.58e-05 | 137 | 31 | 4 | int:RBM27 | |
| Interaction | GTF2B interactions | 6.24e-05 | 141 | 31 | 4 | int:GTF2B | |
| Interaction | SMARCA4 interactions | 6.36e-05 | 462 | 31 | 6 | int:SMARCA4 | |
| Interaction | WDR11 interactions | 6.77e-05 | 144 | 31 | 4 | int:WDR11 | |
| Interaction | NKX3-1 interactions | 6.92e-05 | 52 | 31 | 3 | int:NKX3-1 | |
| Interaction | SUMO1 interactions | 7.10e-05 | 287 | 31 | 5 | int:SUMO1 | |
| Interaction | PCBP2 interactions | 7.21e-05 | 288 | 31 | 5 | int:PCBP2 | |
| Interaction | PURA interactions | 7.57e-05 | 291 | 31 | 5 | int:PURA | |
| Interaction | TLX3 interactions | 7.57e-05 | 291 | 31 | 5 | int:TLX3 | |
| Interaction | MEF2C interactions | 7.75e-05 | 54 | 31 | 3 | int:MEF2C | |
| Interaction | CIITA interactions | 8.19e-05 | 55 | 31 | 3 | int:CIITA | |
| Interaction | EIF3F interactions | 8.21e-05 | 296 | 31 | 5 | int:EIF3F | |
| Interaction | BCL3 interactions | 8.64e-05 | 56 | 31 | 3 | int:BCL3 | |
| Interaction | SRSF4 interactions | 8.74e-05 | 300 | 31 | 5 | int:SRSF4 | |
| Interaction | SNRPA1 interactions | 8.74e-05 | 300 | 31 | 5 | int:SNRPA1 | |
| Interaction | PURB interactions | 9.24e-05 | 156 | 31 | 4 | int:PURB | |
| Interaction | SRSF6 interactions | 1.02e-04 | 503 | 31 | 6 | int:SRSF6 | |
| Interaction | WBP11 interactions | 1.02e-04 | 160 | 31 | 4 | int:WBP11 | |
| Interaction | FOS interactions | 1.05e-04 | 312 | 31 | 5 | int:FOS | |
| Interaction | RBBP7 interactions | 1.06e-04 | 507 | 31 | 6 | int:RBBP7 | |
| Interaction | ANAPC7 interactions | 1.07e-04 | 162 | 31 | 4 | int:ANAPC7 | |
| Interaction | PHF6 interactions | 1.07e-04 | 162 | 31 | 4 | int:PHF6 | |
| Interaction | DDX55 interactions | 1.26e-04 | 169 | 31 | 4 | int:DDX55 | |
| Interaction | MRM3 interactions | 1.26e-04 | 169 | 31 | 4 | int:MRM3 | |
| Interaction | NRIP1 interactions | 1.29e-04 | 170 | 31 | 4 | int:NRIP1 | |
| Interaction | KLF8 interactions | 1.35e-04 | 329 | 31 | 5 | int:KLF8 | |
| Interaction | PRP4K interactions | 1.35e-04 | 329 | 31 | 5 | int:PRP4K | |
| Interaction | POU2F1 interactions | 1.44e-04 | 175 | 31 | 4 | int:POU2F1 | |
| Interaction | SLBP interactions | 1.48e-04 | 67 | 31 | 3 | int:SLBP | |
| Interaction | ESRRA interactions | 1.48e-04 | 67 | 31 | 3 | int:ESRRA | |
| Interaction | CNOT2 interactions | 1.54e-04 | 178 | 31 | 4 | int:CNOT2 | |
| Interaction | LEF1 interactions | 1.61e-04 | 69 | 31 | 3 | int:LEF1 | |
| Interaction | TDG interactions | 1.61e-04 | 69 | 31 | 3 | int:TDG | |
| Interaction | SNRPD1 interactions | 1.73e-04 | 347 | 31 | 5 | int:SNRPD1 | |
| Interaction | ASCC1 interactions | 1.75e-04 | 71 | 31 | 3 | int:ASCC1 | |
| GeneFamily | Zinc fingers ZZ-type|Lysine acetyltransferases | 1.21e-06 | 17 | 23 | 3 | 486 | |
| GeneFamily | Zinc fingers C2H2-type|Sp transcription factors | 5.54e-05 | 9 | 23 | 2 | 755 | |
| GeneFamily | Zinc fingers CCCH-type | 8.98e-04 | 35 | 23 | 2 | 73 | |
| GeneFamily | Nuclear hormone receptors | 1.76e-03 | 49 | 23 | 2 | 71 | |
| GeneFamily | Zinc fingers C2H2-type|ZF class homeoboxes and pseudogenes | 1.81e-03 | 718 | 23 | 5 | 28 | |
| GeneFamily | Basic helix-loop-helix proteins | 8.54e-03 | 110 | 23 | 2 | 420 | |
| Coexpression | GSE8621_UNSTIM_VS_LPS_PRIMED_AND_LPS_STIM_MACROPHAGE_DN | 1.12e-07 | 199 | 31 | 6 | M6987 | |
| Coexpression | LAKE_ADULT_KIDNEY_C11_THIN_ASCENDING_LIMB | 1.56e-06 | 169 | 31 | 5 | M39230 | |
| Coexpression | GSE7831_1H_VS_4H_INFLUENZA_STIM_PDC_DN | 3.47e-06 | 199 | 31 | 5 | M6964 | |
| Coexpression | GSE18281_PERIMEDULLARY_CORTICAL_REGION_VS_WHOLE_CORTEX_THYMUS_UP | 3.56e-06 | 200 | 31 | 5 | M7256 | |
| Coexpression | GSE27241_WT_VS_RORGT_KO_TH17_POLARIZED_CD4_TCELL_TREATED_WITH_DIGOXIN_UP | 5.85e-05 | 180 | 31 | 4 | M8239 | |
| Coexpression | MYLLYKANGAS_AMPLIFICATION_HOT_SPOT_22 | 7.40e-05 | 11 | 31 | 2 | M11594 | |
| Coexpression | GSE15930_NAIVE_VS_72H_IN_VITRO_STIM_TRICHOSTATINA_CD8_TCELL_UP | 8.81e-05 | 200 | 31 | 4 | M3614 | |
| Coexpression | GSE10240_CTRL_VS_IL22_STIM_PRIMARY_BRONCHIAL_EPITHELIAL_CELLS_UP | 8.81e-05 | 200 | 31 | 4 | M302 | |
| Coexpression | TABULA_MURIS_SENIS_MESENTERIC_ADIPOSE_TISSUE_MESENCHYMAL_STEM_CELL_OF_ADIPOSE_AGEING | 1.31e-04 | 685 | 31 | 6 | MM3782 | |
| ToppCell | Brain_organoid-organoid_Paulsen_bioRxiv-1_mon-Proliferating-Cycling_Progenitors|1_mon / Sample Type, Dataset, Time_group, and Cell type. | 2.49e-07 | 199 | 31 | 5 | 358c4b3037f59378db8916a2fbe9ed4830cf1449 | |
| ToppCell | Bronchial-NucSeq|Bronchial / Cell types per location group and 10X technology with lineage, and cell group designations | 1.00e-05 | 196 | 31 | 4 | ab53c742866945545a92e2e61850d63c80d9a2a6 | |
| ToppCell | Parenchymal-NucSeq|Parenchymal / Cell types per location group and 10X technology with lineage, and cell group designations | 1.04e-05 | 198 | 31 | 4 | 1996373bdccc55aac347d349bd22f6aad6d0c668 | |
| ToppCell | COVID-19_Moderate-B_cell|World / disease group, cell group and cell class | 1.22e-04 | 139 | 31 | 3 | b93e1da87d44e55d75e8cc1b87c2970645679c01 | |
| ToppCell | COVID-19_Moderate-B_cell|COVID-19_Moderate / disease group, cell group and cell class | 1.30e-04 | 142 | 31 | 3 | 88bb8d9bca66131df4ee7021b88248e146aa7aa6 | |
| ToppCell | 3'_v3-GI_small-bowel-Lymphocytic_T_CD4-Tregs|GI_small-bowel / Manually curated celltypes from each tissue | 1.68e-04 | 155 | 31 | 3 | d4ef25965a15eab7679478b9b661e1b4a92f1c59 | |
| ToppCell | facs-Marrow-T-cells-24m-Hematologic-MPP_Fraction_B|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 1.84e-04 | 160 | 31 | 3 | b3f7ef7e682b48a83ca425f5c439336e96168300 | |
| ToppCell | renal_cortex_nuclei-Adult_normal_reference-Immune-Lymphocytic_B-Plasma_Cell-|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group | 1.91e-04 | 162 | 31 | 3 | 8ed9149ff53b285591354057055d072b203a47c8 | |
| ToppCell | renal_cortex_nuclei-Adult_normal_reference-Immune-Lymphocytic_B-Plasma_Cell|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group | 1.91e-04 | 162 | 31 | 3 | 7a05b05a33e1309fb5c0a8171db105ae68491815 | |
| ToppCell | 5'-Adult-Appendix-Hematopoietic-Plasma_cells-IgG_plasma_cell|Adult / Celltypes from developing, pediatric, Crohn's, & adult GI tract | 2.02e-04 | 165 | 31 | 3 | 79c6ad394266ff092029375883660028e944a3c8 | |
| ToppCell | VE-Treg-exh_CD4|VE / Condition, Cell_class and T cell subcluster | 2.09e-04 | 167 | 31 | 3 | 1036ac1ef9440612500137af9d1929672b077e4d | |
| ToppCell | Mid-temporal_gyrus_(MTG)-Neuronal-Glutamatergic_Excit-Glut_A_(CT)-Glut_CT2_L6_FEZF2-Exc_L6_FEZF2_SLITRK6|Mid-temporal_gyrus_(MTG) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types | 2.17e-04 | 169 | 31 | 3 | 1c9e54e7b14eb99996590fb93b257cf881a9f184 | |
| ToppCell | Adult-Immune-B_cell-D175|Adult / Lineage, Cell type, age group and donor | 2.24e-04 | 171 | 31 | 3 | 355a246f3395900342d400f6f7c6640cba0d4d5d | |
| ToppCell | PBMC-Mild-Lymphocyte-B-B_cell-B_naive-B_naive-4|Mild / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01) | 2.28e-04 | 172 | 31 | 3 | 62ed3b70fa1f6c84ea80ff00f60d2562be292e9d | |
| ToppCell | PBMC-Convalescent-Lymphocyte-B-B_cell-B_intermediate-B_intermediate-10|Convalescent / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01) | 2.36e-04 | 174 | 31 | 3 | 59ccc5a82507463e0a316ba6286cb25ec1a4091b | |
| ToppCell | Primary_Visual_cortex_(V1C)-Neuronal-Glutamatergic_Excit-Glut_A_(CT)-Glut_CT2_L6_FEZF2-Exc_L6_FEZF2_SLITRK6|Primary_Visual_cortex_(V1C) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types | 2.48e-04 | 177 | 31 | 3 | 62f180d5a487b449f715de49ee1e1e11c4e0cf4d | |
| ToppCell | E12.5-Mesenchymal-myocytic_cell-vascular_associated_smooth_muscle_cell|E12.5 / developmental_time, Lineage, Cell group, Cell type, Cell type_cellcyc-phase | 2.48e-04 | 177 | 31 | 3 | 5cdf413f82376a95467322b16d10b0d1e7557e2d | |
| ToppCell | B_cells-Naive_B_cells_|B_cells / Immune cells in Kidney/Urine in Lupus Nephritis | 2.52e-04 | 178 | 31 | 3 | 71ac2eca5cf13a91f86b80690748b0788392dcfc | |
| ToppCell | Control-Lymphocyte-B-B_naive|Control / Disease, Lineage and Cell Type | 2.56e-04 | 179 | 31 | 3 | 35994281904bfe38766e715ab608211a5ca865a9 | |
| ToppCell | COVID-19_Mild-NK_CD56bright|COVID-19_Mild / Disease condition and Cell class | 2.56e-04 | 179 | 31 | 3 | 90e7a4af195aa2332b07a9f06cde63e72ff49255 | |
| ToppCell | Leuk-UTI-Lymphocyte-B-B_naive|Leuk-UTI / Disease, Lineage and Cell Type | 2.65e-04 | 181 | 31 | 3 | fb0b5a94796b99c64091f9890f7a09c39bbc3f73 | |
| ToppCell | renal_medulla_nuclei-Hypertensive_with+without-CKD-Immune-Lymphocytic_B-Plasma_Cell|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group | 2.65e-04 | 181 | 31 | 3 | 6cdee2f56bc633b387b4dbbd78c624edbd712c24 | |
| ToppCell | renal_medulla_nuclei-Hypertensive_with+without-CKD-Immune-Lymphocytic_B-Plasma_Cell-|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group | 2.65e-04 | 181 | 31 | 3 | b75b8b025257bccfe661fd0f92ab284b2a9c12ee | |
| ToppCell | PBMC-Severe-Lymphocyte-B-B_cell-B_naive-B_naive-8|Severe / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01) | 2.65e-04 | 181 | 31 | 3 | ca34d83daca10c5fa52ecdf4eba7d31b4e7e056e | |
| ToppCell | Influenza_Severe-B_naive|World / Disease group and Cell class | 2.69e-04 | 182 | 31 | 3 | e4885a5e6065c9c403cb2d305228691d6ae4ecb6 | |
| ToppCell | wk_20-22-Mesenchymal-Chondrocyte-intermediate_chondrocyte|wk_20-22 / Celltypes from embryonic and fetal-stage human lung | 2.74e-04 | 183 | 31 | 3 | 1464b5c4425e8776c4aeb4d2b560481d4bf13931 | |
| ToppCell | COVID-19-B_cells|COVID-19 / group, cell type (main and fine annotations) | 2.74e-04 | 183 | 31 | 3 | 2c016bb59f131a0e821853b085289a3583f0a729 | |
| ToppCell | PBMC_fresh-frozen-Mild-Moderate_progression_d12-25-Lymphocytic-Lymphocytic_T-mature_alpha-beta_T_cell-T_CD4_c01-LEF1|Mild-Moderate_progression_d12-25 / Compartment, severity and other cell annotations on 10x 3' data (130k) | 2.78e-04 | 184 | 31 | 3 | bd786db4dc4edae6d5cfc0b69901983dea19f729 | |
| ToppCell | Bac-SEP-Lymphocyte-B-B_naive|Bac-SEP / Disease, Lineage and Cell Type | 2.82e-04 | 185 | 31 | 3 | 4d9e1eeb353c0b1f82f557856e99c8bf04aa2a7f | |
| ToppCell | Control-Lymphocyte-B|Control / Disease, Lineage and Cell Type | 2.82e-04 | 185 | 31 | 3 | cb61b5ff6a2ef71c94469c35cafc21df5bcf61b1 | |
| ToppCell | URO-Lymphocyte-B|URO / Disease, Lineage and Cell Type | 2.87e-04 | 186 | 31 | 3 | c46ff4fc280b67a454ee9614e93c6854a5a400b8 | |
| ToppCell | TCGA-Pancreas-Primary_Tumor-Pancreatic_Adenocarcinoma-Ductal_Adenocarcinoma-1|TCGA-Pancreas / Sample_Type by Project: Shred V9 | 2.87e-04 | 186 | 31 | 3 | 03db813598b67b1e08f759758a1c2023396921fa | |
| ToppCell | 10x5'-Liver-Lymphocytic_B-Naive_B_cells|Liver / Manually curated celltypes from each tissue | 2.87e-04 | 186 | 31 | 3 | 23efdcedbe67f5e6c59106e052f570cd0338f1c1 | |
| ToppCell | PBMC-Mild-Lymphocyte-B-B_cell-B_naive-B_naive-8|Mild / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01) | 2.92e-04 | 187 | 31 | 3 | c10d6a774b3e83f64e47b9ad08f5d6b0dc60d163 | |
| ToppCell | URO-Lymphocyte-B-B_naive|URO / Disease, Lineage and Cell Type | 2.92e-04 | 187 | 31 | 3 | 9ed6a39aae7126ddbd01aec3376113b6b4517383 | |
| ToppCell | Smart-seq2-blood_(Smart-seq2)-lymphocytic-B_lymphocytic-naive_B_cell|blood_(Smart-seq2) / Per Platform+tissue_group, by lineage_subgroup, cell_group, cell_type | 2.92e-04 | 187 | 31 | 3 | 160e5f338537d90d50f863a1be801b1071ac7da7 | |
| ToppCell | LPS-IL1RA-Epithelial_alveolar-AT_2-Differentiating_AT2|LPS-IL1RA / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 2.96e-04 | 188 | 31 | 3 | 4bdf8d49af0e9da349b16e3f012e1b0eec04cc4f | |
| ToppCell | facs-Heart-RA-3m-Endothelial-endocardial_cell|Heart / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 2.96e-04 | 188 | 31 | 3 | 4ddb11a90bf3baa7237bde304db44dfcc56aed52 | |
| ToppCell | 10x5'-blood-Lymphocytic_B-Naive_B_cells|blood / Manually curated celltypes from each tissue | 2.96e-04 | 188 | 31 | 3 | 2b3560b28f9df6f4d4a3e0a4acfa6c7d964ad0fe | |
| ToppCell | facs-Heart-RA-3m-Endothelial-endothelial_cell_of_endocardium|Heart / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 2.96e-04 | 188 | 31 | 3 | e47e66906922d5c69b1aafe28face0787d3fc563 | |
| ToppCell | P07-Endothelial-large_vessel_endothelial_cell-endothelial_cell_of_artery|P07 / developmental_time, Lineage, Cell group, Cell type, Cell type_cellcyc-phase | 2.96e-04 | 188 | 31 | 3 | 5bc1537e079c7435196c163bff5f639ea392a33a | |
| ToppCell | PBMC_fresh-frozen-Severe-critical_progression_d03-09-Lymphocytic-Lymphocytic_B-B_cell-B_c01-TCL1A|Severe-critical_progression_d03-09 / Compartment, severity and other cell annotations on 10x 3' data (130k) | 2.96e-04 | 188 | 31 | 3 | d8decd9b5967873ca8320c2f9f07365f163c777f | |
| ToppCell | COVID-19-lung-Plasma_cells_PRDM1/BLIMP_hi|COVID-19 / Disease (COVID-19 only), tissue and cell type | 2.96e-04 | 188 | 31 | 3 | 567b08514d9d84cbb40f9b7a679eec304f023428 | |
| ToppCell | Healthy-B_naive|World / disease group, cell group and cell class | 3.01e-04 | 189 | 31 | 3 | 1e533a43f739ff295740cf2b25479756dfb8e595 | |
| ToppCell | droplet-Kidney-KIDNEY-30m-Endothelial|Kidney / Skin_Bladder_Kidney_Mammary_Gland - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 3.01e-04 | 189 | 31 | 3 | 92319bef1f00d6048ba8f9f8b5c6dbb896686b74 | |
| ToppCell | 10x_3'_v3-tissue-resident_(10x_3'_v3)-lymphocytic-B_lymphocytic-naive_B_cell|tissue-resident_(10x_3'_v3) / Per Platform+tissue_group, by lineage_subgroup, cell_group, cell_type | 3.05e-04 | 190 | 31 | 3 | a7498fe55b7810c482291db782dc5282675d246a | |
| ToppCell | Severe-MAIT|World / Disease group and Cell class | 3.05e-04 | 190 | 31 | 3 | 7a92e0d6a021be23125495927b8571e25c83204a | |
| ToppCell | severe-B_naive|World / disease stage, cell group and cell class | 3.05e-04 | 190 | 31 | 3 | 8dfe067d75573289299a5fba42b6c9b26e5fb430 | |
| ToppCell | severe-B_naive|severe / disease stage, cell group and cell class | 3.05e-04 | 190 | 31 | 3 | 2430a1fd18385305bf1b604747ff64026a8d5edf | |
| ToppCell | Severe-MAIT|Severe / Disease group and Cell class | 3.05e-04 | 190 | 31 | 3 | 1c063dc1b62d9f9912aaf8d0297555a6545f5550 | |
| ToppCell | PBMC-Mild-Lymphocyte-B-B_cell-B_naive-B_activate-7|Mild / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01) | 3.10e-04 | 191 | 31 | 3 | 2feab42ac6d29fa4eac78f3f78a5f8aa0a559523 | |
| ToppCell | Smart-seq2-blood_(Smart-seq2)-lymphocytic-B_lymphocytic|blood_(Smart-seq2) / Per Platform+tissue_group, by lineage_subgroup, cell_group, cell_type | 3.10e-04 | 191 | 31 | 3 | 3fc16e986aff5e0cd4f831e25e78a5b30beba7a8 | |
| ToppCell | 10x3'2.3-week_17-19-Lymphocytic_B-B_lineage-naive_B_cell|week_17-19 / cell types per 3 fetal stages;per 3',per 5' | 3.10e-04 | 191 | 31 | 3 | a073d58154c801ec499fd969f42b7f1ee7f15d79 | |
| ToppCell | PND10-Endothelial-Endothelial_blood-vessel-Macrovascular_EC|PND10 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif | 3.10e-04 | 191 | 31 | 3 | b270c3dd5952f56b9bdceabe13e298fe6757563b | |
| ToppCell | PBMC-Mild-Lymphocyte-B-B_cell-B_intermediate-B_intermediate-0|Mild / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01) | 3.10e-04 | 191 | 31 | 3 | 5a9a592875fbd0b1429b48db29a760fdc9c2c856 | |
| ToppCell | ICU-SEP-Lymphocyte-B-B_naive|ICU-SEP / Disease, Lineage and Cell Type | 3.10e-04 | 191 | 31 | 3 | a090f9ea58a700c995c4ad35eeebb699f07040f7 | |
| ToppCell | PBMC-Severe-Lymphocyte-B-B_cell-B_intermediate-B_intermediate-0|Severe / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01) | 3.10e-04 | 191 | 31 | 3 | b7d17d3ba488378b30f3732f8109f4a7c1673e61 | |
| ToppCell | facs-Kidney-nan-18m-Endothelial-fenestrated_cell|Kidney / Skin_Bladder_Kidney_Mammary_Gland - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 3.15e-04 | 192 | 31 | 3 | 777e386a17bba9ec450bb9d64d8a9ab98d9a63ff | |
| ToppCell | facs-Kidney-nan-18m-Endothelial|Kidney / Skin_Bladder_Kidney_Mammary_Gland - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 3.15e-04 | 192 | 31 | 3 | 60a2409546525a40a5658e0f9d6a50c37f28bb96 | |
| ToppCell | 10x5'-bone_marrow-Lymphocytic_B-Naive_B_cells|bone_marrow / Manually curated celltypes from each tissue | 3.15e-04 | 192 | 31 | 3 | fa99243ff028498c6a67d207a93e02c48e69cd42 | |
| ToppCell | PBMC-Control-Lymphocyte-B-B_cell-B_intermediate-B_intermediate-0|Control / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01) | 3.15e-04 | 192 | 31 | 3 | 89b8ebdc285ed3c0f807fd1157271130d37dfa41 | |
| ToppCell | PBMC-Control-Lymphocyte-B-B_cell-B_naive-B_naive-2|Control / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01) | 3.15e-04 | 192 | 31 | 3 | ef86d82e4f04f9f54e821ef496d70fc81072d773 | |
| ToppCell | Healthy/Control-B_intermediate|World / Disease group and Cell class | 3.15e-04 | 192 | 31 | 3 | 2266aa695955f5d885708e6bc0d5a8827c306223 | |
| ToppCell | facs-Kidney-nan-18m-Endothelial-Pecam____fenestrated_capillary_endothelial|Kidney / Skin_Bladder_Kidney_Mammary_Gland - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 3.15e-04 | 192 | 31 | 3 | 0f9db6091b373334b9beabe0e5782bf2bc54690b | |
| ToppCell | 10x_3'_v3-blood_(10x_3'_v3)-lymphocytic-B_lymphocytic-naive_B_cell|blood_(10x_3'_v3) / Per Platform+tissue_group, by lineage_subgroup, cell_group, cell_type | 3.15e-04 | 192 | 31 | 3 | 800edadd1d1ba6b7e0a0398030dd4b61c9c480c7 | |
| ToppCell | PBMC-Mild-Lymphocyte-B-B_cell-B_naive-B_naive-9|Mild / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01) | 3.20e-04 | 193 | 31 | 3 | d5d188a314da1b4c8390276d88173c09dd7ce4bf | |
| ToppCell | severe_influenza-B_naive|World / disease group, cell group and cell class (v2) | 3.20e-04 | 193 | 31 | 3 | c52ba94782ad57b93d20f853a89344dffa8351f9 | |
| ToppCell | droplet-Heart-HEART-1m-Endothelial-endocardial_cell|Heart / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 3.20e-04 | 193 | 31 | 3 | d0a5f212f8e8a13dbbe3e41df92548ef82eef70b | |
| ToppCell | Control-NK_CD56bright|Control / Disease condition and Cell class | 3.20e-04 | 193 | 31 | 3 | 8b1e7a226a6057e1097c1525984127b54e823876 | |
| ToppCell | systemic_lupus_erythematosus-managed-Lymphocytic_B-B_naive-female|systemic_lupus_erythematosus / PBMC cell types (v2) per disease, treatment status, and sex | 3.20e-04 | 193 | 31 | 3 | 95ec708d963e9411e2dcf65650ae71a26e9d0e7f | |
| ToppCell | systemic_lupus_erythematosus-managed-Lymphocytic_B-B_naive|systemic_lupus_erythematosus / PBMC cell types (v2) per disease, treatment status, and sex | 3.20e-04 | 193 | 31 | 3 | d0d0835304647758e6ad4348402a4f76a76137a0 | |
| ToppCell | PND03-Endothelial-Endothelial_blood-vessel-Macrovascular_EC|PND03 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif | 3.20e-04 | 193 | 31 | 3 | 58c590dd6f21bc7ae58ae1729dd574c0f1069592 | |
| ToppCell | PBMC_fresh-frozen-Severe-critical_progression_d12-22_no-steroids-Lymphocytic-Lymphocytic_B|Severe-critical_progression_d12-22_no-steroids / Compartment, severity and other cell annotations on 10x 3' data (130k) | 3.20e-04 | 193 | 31 | 3 | ac227ddabfb3f021b1b39dba73f898517cd5a58e | |
| ToppCell | COVID_non-vent-Lymphocytic-B_cell-|COVID_non-vent / Disease condition, Lineage, Cell class and subclass | 3.20e-04 | 193 | 31 | 3 | 91955c3773c9729a96e82f240f06b072367970d9 | |
| ToppCell | PBMC_fresh-frozen-Severe-critical_progression_d12-22_no-steroids-Lymphocytic-Lymphocytic_B-B_cell|Severe-critical_progression_d12-22_no-steroids / Compartment, severity and other cell annotations on 10x 3' data (130k) | 3.20e-04 | 193 | 31 | 3 | f4135615ee0118eec9e221becdd67888e0c2a112 | |
| ToppCell | COVID_non-vent-Lymphocytic-B_cell|COVID_non-vent / Disease condition, Lineage, Cell class and subclass | 3.20e-04 | 193 | 31 | 3 | 32d139f922cd19adc1cc1e0e9a828115be9945d6 | |
| ToppCell | PBMC_fresh-frozen-Severe-critical_progression_d12-22_no-steroids-Lymphocytic-Lymphocytic_B-B_cell-B_c02-MS4A1-CD27|Severe-critical_progression_d12-22_no-steroids / Compartment, severity and other cell annotations on 10x 3' data (130k) | 3.25e-04 | 194 | 31 | 3 | 5cd72330c9d9bb21b6c9d5d35085eade101486d1 | |
| ToppCell | severe_influenza-B_naive|severe_influenza / disease group, cell group and cell class (v2) | 3.25e-04 | 194 | 31 | 3 | 7c1e9ce5de3bb1657a67010de673c8bb60129cb6 | |
| ToppCell | PBMC-Control-Lymphocyte-B-B_cell-B_naive-B_naive-8|Control / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01) | 3.25e-04 | 194 | 31 | 3 | e9c907b8ec4329946338cca5ce8e954fa2cec37b | |
| ToppCell | PBMC-Severe-Lymphocyte-B-B_cell-B_naive-B_naive-4|Severe / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01) | 3.25e-04 | 194 | 31 | 3 | 24f9de4781666c96c4a2d04f8a444543dbd99cbe | |
| ToppCell | COVID-19_Moderate-B_naive|World / disease group, cell group and cell class | 3.25e-04 | 194 | 31 | 3 | 1f81d618799e482a36dce528bba70f52cc69a901 | |
| ToppCell | Control-Lymphoid_B-B_naive|Control / Disease group, lineage and cell class | 3.25e-04 | 194 | 31 | 3 | 4f9600960a287cfc020c06b4af3528d4e5797916 | |
| ToppCell | Smart-seq2-lymph_node_(Smart-seq2)-lymphocytic-B_lymphocytic-B_cell|lymph_node_(Smart-seq2) / Per Platform+tissue_group, by lineage_subgroup, cell_group, cell_type | 3.25e-04 | 194 | 31 | 3 | ff661419b697aef51a53fdeac8d37d870d65f491 | |
| ToppCell | COVID-19_Severe-B_naive|World / disease group, cell group and cell class | 3.25e-04 | 194 | 31 | 3 | d363963a6caeedf4f9e9ad22dcf9b66b85c79a48 | |
| ToppCell | CV-Severe-6|Severe / Virus stimulation, Condition and Cluster | 3.25e-04 | 194 | 31 | 3 | d33be6ed1de907aeea0c2dce09796556b8efdd4e | |
| ToppCell | PBMC-Severe-Lymphocyte-B-B_cell-B_naive-B_naive-2|Severe / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01) | 3.25e-04 | 194 | 31 | 3 | 36ce99b9e4e1c968cc7ae381168124cc7c14afb2 | |
| ToppCell | COVID-19_Moderate-B_naive|COVID-19_Moderate / disease group, cell group and cell class | 3.25e-04 | 194 | 31 | 3 | 8c41a37467bfd4966ecd09dde68c543dc01b6ad0 | |
| ToppCell | PBMC-Severe-Lymphocyte-B-B_cell-B_naive|Severe / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01) | 3.25e-04 | 194 | 31 | 3 | 82753b90ca3b563275c41b6040ebbcd99b185e24 | |
| ToppCell | PBMC-Mild-Lymphocyte-B-B_cell-B_naive|Mild / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01) | 3.25e-04 | 194 | 31 | 3 | 287439c51528d7bb13bd235875d85631dc91ed91 | |
| ToppCell | PBMC-Severe-Lymphocyte-B-B_cell-B_naive|Severe / Location, Disease Group, Cell group, Cell class (2021.03.09) | 3.30e-04 | 195 | 31 | 3 | e830f0c545be87a1056a4505bdf6845e5ac7750d | |
| ToppCell | Influenza_Severe-B_naive|Influenza_Severe / Disease group and Cell class | 3.30e-04 | 195 | 31 | 3 | a25516ed670c7738670ffbaa6f7cd167946f3825 | |
| ToppCell | CV-Severe-6|CV / Virus stimulation, Condition and Cluster | 3.30e-04 | 195 | 31 | 3 | 69095c6ce2a7e763afa543c10d5710e0c3dda769 | |
| ToppCell | Healthy_donor-B_naive|World / disease group, cell group and cell class (v2) | 3.30e-04 | 195 | 31 | 3 | c66bbfdf0091cc62aa50edfa88820bbda191b7bb | |
| ToppCell | PBMC-Mild-Lymphocyte-B-B_cell-B_naive-|Mild / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.09) | 3.30e-04 | 195 | 31 | 3 | 4b882a71f0e02fef5580e9d9bc42245cf9df2e57 | |
| ToppCell | PBMC-Mild-Lymphocyte-B-B_cell-B_naive|Mild / Location, Disease Group, Cell group, Cell class (2021.03.09) | 3.30e-04 | 195 | 31 | 3 | b74645072a063732d5be43036ce0e9568eff3d14 | |
| ToppCell | mild_COVID-19_(asymptomatic)-B_naive|World / disease group, cell group and cell class (v2) | 3.30e-04 | 195 | 31 | 3 | e763d9a431052c03cc6d514f2736506c6667e2be | |
| ToppCell | severe_COVID-19-B_naive|World / disease group, cell group and cell class (v2) | 3.30e-04 | 195 | 31 | 3 | e6c77119494b787c44502c0390fb2c86a34b1846 | |
| ToppCell | droplet-Heart-4Chambers-21m-Endothelial-endocardial_cell|Heart / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 3.30e-04 | 195 | 31 | 3 | df644b4c3ddccd34614ece5a2378000e6bc0fa10 | |
| ToppCell | 10x5'-bone_marrow-Lymphocytic_B|bone_marrow / Manually curated celltypes from each tissue | 3.30e-04 | 195 | 31 | 3 | bcbf0305ca9337a6f3021178dbb47a7fbf1030a4 | |
| ToppCell | COVID-19_Severe-Lymphoid_B-B_naive|COVID-19_Severe / Disease group, lineage and cell class | 3.30e-04 | 195 | 31 | 3 | 71563e838fcda34a9a209c5433e0d84420373402 | |
| Drug | Trichostatin A, Streptomyces sp.; Down 200; 0.1uM; MCF7; HT_HG-U133A_EA | 2.01e-09 | 170 | 30 | 7 | 1050_DN | |
| Drug | Trichostatin A, Streptomyces sp.; Down 200; 1uM; MCF7; HT_HG-U133A_EA | 2.18e-09 | 172 | 30 | 7 | 1072_DN | |
| Drug | SAHA; Down 200; 10uM; MCF7; HT_HG-U133A_EA | 2.46e-09 | 175 | 30 | 7 | 1058_DN | |
| Drug | 2',3',4',5'-tetrachloro-4-biphenylol | 4.12e-08 | 6 | 30 | 3 | ctd:C104006 | |
| Drug | AC1L9M2J | 4.84e-08 | 76 | 30 | 5 | CID000448538 | |
| Drug | Trichostatin A, Streptomyces sp.; Down 200; 0.1uM; MCF7; HT_HG-U133A_EA | 1.07e-07 | 178 | 30 | 6 | 1112_DN | |
| Drug | Androstenols | 4.51e-07 | 12 | 30 | 3 | ctd:D000737 | |
| Drug | bicalutamide | 5.88e-07 | 125 | 30 | 5 | CID000002375 | |
| Drug | ferutinin | 1.14e-06 | 16 | 30 | 3 | CID000354654 | |
| Drug | bis(4-oxyphenyl)sulfide | 1.68e-06 | 2 | 30 | 2 | ctd:C069693 | |
| Drug | Phosphites | 1.68e-06 | 2 | 30 | 2 | ctd:D017905 | |
| Drug | galangin | 1.88e-06 | 68 | 30 | 4 | ctd:C037032 | |
| Drug | Trichostatin A, from Streptomyces sp.; Down 200; 0.1uM; MCF7; HT_HG-U133A | 2.18e-06 | 163 | 30 | 5 | 7453_DN | |
| Drug | Trichostatin A, from Streptomyces sp.; Down 200; 0.1uM; MCF7; HT_HG-U133A | 2.32e-06 | 165 | 30 | 5 | 5625_DN | |
| Drug | Trichostatin A, from Streptomyces sp.; Down 200; 0.1uM; MCF7; HT_HG-U133A | 2.32e-06 | 165 | 30 | 5 | 2835_DN | |
| Drug | Trichostatin A, from Streptomyces sp.; Down 200; 0.1uM; MCF7; HT_HG-U133A | 2.38e-06 | 166 | 30 | 5 | 2247_DN | |
| Drug | Trichostatin A, Streptomyces sp.; Down 200; 1uM; MCF7; HT_HG-U133A | 2.60e-06 | 169 | 30 | 5 | 5231_DN | |
| Drug | trichostatin A, Streptomyces sp.; Down 200; 1uM; MCF7; HT_HG-U133A | 2.68e-06 | 170 | 30 | 5 | 7043_DN | |
| Drug | Trichostatin A, from Streptomyces sp.; Down 200; 0.1uM; MCF7; HT_HG-U133A | 2.84e-06 | 172 | 30 | 5 | 2330_DN | |
| Drug | Trichostatin A, from Streptomyces sp.; Down 200; 0.1uM; MCF7; HT_HG-U133A | 2.92e-06 | 173 | 30 | 5 | 2881_DN | |
| Drug | trichostatin A, Streptomyces sp.; Down 200; 1uM; PC3; HT_HG-U133A | 2.92e-06 | 173 | 30 | 5 | 5950_DN | |
| Drug | Trichostatin A, from Streptomyces sp.; Down 200; 0.1uM; MCF7; HT_HG-U133A | 3.00e-06 | 174 | 30 | 5 | 5693_DN | |
| Drug | trichostatin A, Streptomyces sp.; Down 200; 1uM; MCF7; HT_HG-U133A | 3.09e-06 | 175 | 30 | 5 | 5935_DN | |
| Drug | Trichostatin A, Streptomyces sp.; Down 200; 1uM; MCF7; HT_HG-U133A_EA | 3.09e-06 | 175 | 30 | 5 | 1014_DN | |
| Drug | Trichostatin A, from Streptomyces sp.; Down 200; 0.1uM; MCF7; HT_HG-U133A | 3.18e-06 | 176 | 30 | 5 | 3312_DN | |
| Drug | trichostatin A ; Down 200; 1uM; MCF7; HT_HG-U133A_EA | 3.18e-06 | 176 | 30 | 5 | 981_DN | |
| Drug | Trichostatin A, Streptomyces sp.; Down 200; 0.1uM; MCF7; HT_HG-U133A | 3.18e-06 | 176 | 30 | 5 | 6932_DN | |
| Drug | trichostatin A, Streptomyces sp.; Down 200; 1uM; MCF7; HT_HG-U133A | 3.27e-06 | 177 | 30 | 5 | 6434_DN | |
| Drug | Trichostatin A, from Streptomyces sp.; Down 200; 0.1uM; PC3; HT_HG-U133A | 3.45e-06 | 179 | 30 | 5 | 6609_DN | |
| Drug | Trichostatin A, from Streptomyces sp.; Down 200; 0.1uM; MCF7; HT_HG-U133A | 3.55e-06 | 180 | 30 | 5 | 6454_DN | |
| Drug | Trichostatin A, Streptomyces sp.; Down 200; 1uM; MCF7; HT_HG-U133A | 3.64e-06 | 181 | 30 | 5 | 6951_DN | |
| Drug | Diethylstilbestrol | 3.86e-06 | 1305 | 30 | 10 | ctd:D004054 | |
| Drug | SAHA; Down 200; 10uM; MCF7; HT_HG-U133A | 3.95e-06 | 184 | 30 | 5 | 6939_DN | |
| Drug | holotoxin A1 | 5.03e-06 | 3 | 30 | 2 | CID000119551 | |
| Drug | 2-propylpentanoic acid; Down 200; 1000uM; MCF7; HG-U133A | 5.65e-06 | 198 | 30 | 5 | 23_DN | |
| Drug | tetrac | 7.37e-06 | 29 | 30 | 3 | CID000065552 | |
| Drug | CV-1 | 8.05e-06 | 213 | 30 | 5 | CID000130105 | |
| Drug | AC1L9FY1 | 9.15e-06 | 101 | 30 | 4 | CID000444218 | |
| Drug | terics | 1.01e-05 | 4 | 30 | 2 | ctd:C021754 | |
| Drug | MDL 28564 | 1.01e-05 | 4 | 30 | 2 | CID000180453 | |
| Drug | AC1L9K70 | 1.12e-05 | 228 | 30 | 5 | CID000446871 | |
| Drug | Physalemin | 1.31e-05 | 35 | 30 | 3 | CID000017268 | |
| Drug | empenthrin | 1.67e-05 | 5 | 30 | 2 | CID006434488 | |
| Drug | dioxybenzone | 1.67e-05 | 5 | 30 | 2 | ctd:C004839 | |
| Drug | MF101 extract | 1.67e-05 | 5 | 30 | 2 | ctd:C517398 | |
| Drug | 3-benzylidene camphor | 1.67e-05 | 5 | 30 | 2 | ctd:C511303 | |
| Drug | 4-ethoxymethylphenol | 1.67e-05 | 5 | 30 | 2 | CID000093781 | |
| Drug | AC1ND2OB | 2.31e-05 | 265 | 30 | 5 | CID004568637 | |
| Drug | 8-oxyguanine | 2.48e-05 | 130 | 30 | 4 | CID000119315 | |
| Drug | butamben | 2.51e-05 | 6 | 30 | 2 | ctd:C004605 | |
| Drug | hydroxypropyl methacrylate | 2.51e-05 | 6 | 30 | 2 | CID000034023 | |
| Drug | tegaserod | 2.51e-05 | 6 | 30 | 2 | ctd:C105050 | |
| Drug | silyl | 2.82e-05 | 45 | 30 | 3 | CID000139580 | |
| Drug | Epirubicin | 3.22e-05 | 47 | 30 | 3 | ctd:D015251 | |
| Drug | tb-E | 3.22e-05 | 47 | 30 | 3 | CID000006588 | |
| Drug | 4,4'-hexafluorisopropylidene diphenol | 3.50e-05 | 142 | 30 | 4 | ctd:C583074 | |
| Drug | 1H,1H,2H,2H-perfluorooctan-1-ol | 3.51e-05 | 7 | 30 | 2 | CID000069537 | |
| Drug | estratriene | 3.51e-05 | 7 | 30 | 2 | CID000150899 | |
| Drug | cilnidipine | 3.51e-05 | 7 | 30 | 2 | ctd:C065927 | |
| Drug | 8:2 FTOH | 3.51e-05 | 7 | 30 | 2 | CID000069619 | |
| Drug | lacidipine | 3.51e-05 | 7 | 30 | 2 | ctd:C060285 | |
| Drug | L-T3-PAL | 3.51e-05 | 7 | 30 | 2 | CID005487638 | |
| Drug | selamectin | 3.51e-05 | 7 | 30 | 2 | ctd:C414354 | |
| Drug | AC1O5TPK | 4.12e-05 | 51 | 30 | 3 | CID006440511 | |
| Drug | N-desmethyl-tamoxifen-hydrochloride | 4.37e-05 | 52 | 30 | 3 | CID000035887 | |
| Drug | AC1L2E0P | 4.66e-05 | 307 | 30 | 5 | CID000019390 | |
| Drug | 1H,1H,2H,2H-perfluorooctan-1-ol | 4.68e-05 | 8 | 30 | 2 | ctd:C508406 | |
| Drug | ormeloxifene | 4.68e-05 | 8 | 30 | 2 | ctd:C508548 | |
| Drug | LY 353381 | 4.68e-05 | 8 | 30 | 2 | ctd:C115121 | |
| Drug | Methyltestosterone | 4.89e-05 | 54 | 30 | 3 | ctd:D008777 | |
| Drug | pregna-4,17-diene-3,16-dione | 5.17e-05 | 55 | 30 | 3 | ctd:C023617 | |
| Drug | tris(chloroethyl)phosphate | 5.17e-05 | 55 | 30 | 3 | ctd:C031324 | |
| Drug | A25618 | 5.38e-05 | 777 | 30 | 7 | CID000005562 | |
| Drug | Trichostatin A, from Streptomyces sp.; Down 200; 0.1uM; MCF7; HT_HG-U133A | 5.72e-05 | 161 | 30 | 4 | 4768_DN | |
| Drug | 4-phenylphenol | 6.01e-05 | 9 | 30 | 2 | ctd:C019046 | |
| Drug | 2-acetyltributylcitrate | 6.01e-05 | 9 | 30 | 2 | ctd:C014953 | |
| Drug | AF-5 | 6.01e-05 | 9 | 30 | 2 | CID005463920 | |
| Drug | Trichostatin A, from Streptomyces sp.; Down 200; 0.1uM; MCF7; HT_HG-U133A | 6.44e-05 | 166 | 30 | 4 | 7324_DN | |
| Drug | Trichostatin A, from Streptomyces sp.; Down 200; 0.1uM; MCF7; HT_HG-U133A | 6.44e-05 | 166 | 30 | 4 | 2268_DN | |
| Drug | SAHA; Down 200; 10uM; MCF7; HT_HG-U133A | 6.59e-05 | 167 | 30 | 4 | 5217_DN | |
| Drug | Trichostatin A, from Streptomyces sp.; Down 200; 0.1uM; MCF7; HT_HG-U133A | 6.75e-05 | 168 | 30 | 4 | 3868_DN | |
| Drug | Trichostatin A, from Streptomyces sp.; Down 200; 0.1uM; MCF7; HT_HG-U133A | 6.75e-05 | 168 | 30 | 4 | 6820_DN | |
| Drug | Trichostatin A, from Streptomyces sp.; Down 200; 0.1uM; MCF7; HT_HG-U133A | 6.91e-05 | 169 | 30 | 4 | 6064_DN | |
| Drug | Trichostatin A, from Streptomyces sp.; Down 200; 0.1uM; PC3; HT_HG-U133A | 7.07e-05 | 170 | 30 | 4 | 3791_DN | |
| Drug | SAHA; Down 200; 10uM; MCF7; HT_HG-U133A_EA | 7.23e-05 | 171 | 30 | 4 | 1000_DN | |
| Drug | irinotecan HCl; Down 200; 100uM; PC3; HT_HG-U133A | 7.23e-05 | 171 | 30 | 4 | 7535_DN | |
| Drug | trichostatin A, Streptomyces sp.; Down 200; 1uM; MCF7; HT_HG-U133A | 7.23e-05 | 171 | 30 | 4 | 6879_DN | |
| Drug | Trichostatin A, from Streptomyces sp.; Down 200; 0.1uM; MCF7; HT_HG-U133A | 7.39e-05 | 172 | 30 | 4 | 7179_DN | |
| Drug | Trichostatin A, from Streptomyces sp.; Down 200; 0.1uM; MCF7; HT_HG-U133A | 7.39e-05 | 172 | 30 | 4 | 3428_DN | |
| Drug | Trichostatin A, from Streptomyces sp.; Down 200; 0.1uM; MCF7; HT_HG-U133A | 7.39e-05 | 172 | 30 | 4 | 2794_DN | |
| Drug | iclaprim | 7.41e-05 | 62 | 30 | 3 | CID000213043 | |
| Drug | Valinomycin | 7.50e-05 | 10 | 30 | 2 | ctd:D014634 | |
| Drug | SP 0 | 7.50e-05 | 10 | 30 | 2 | CID002742752 | |
| Drug | Trichostatin A, from Streptomyces sp.; Down 200; 0.1uM; PC3; HT_HG-U133A | 7.56e-05 | 173 | 30 | 4 | 4665_DN | |
| Drug | Trichostatin A, from Streptomyces sp.; Down 200; 0.1uM; MCF7; HT_HG-U133A | 7.56e-05 | 173 | 30 | 4 | 5987_DN | |
| Drug | Trichostatin A, from Streptomyces sp.; Down 200; 0.1uM; MCF7; HT_HG-U133A | 7.56e-05 | 173 | 30 | 4 | 5336_DN | |
| Drug | Trichostatin A, from Streptomyces sp.; Down 200; 0.1uM; MCF7; HT_HG-U133A | 7.56e-05 | 173 | 30 | 4 | 3243_DN | |
| Drug | trichostatin A, Streptomyces sp.; Down 200; 1uM; MCF7; HT_HG-U133A | 7.73e-05 | 174 | 30 | 4 | 6579_DN | |
| Drug | Trichostatin A, from Streptomyces sp.; Down 200; 0.1uM; PC3; HT_HG-U133A | 7.73e-05 | 174 | 30 | 4 | 5745_DN | |
| Drug | Trichostatin A, Streptomyces sp.; Down 200; 1uM; MCF7; HT_HG-U133A | 7.73e-05 | 174 | 30 | 4 | 1659_DN | |
| Disease | breast carcinoma (is_marker_for) | 6.86e-07 | 66 | 31 | 4 | DOID:3459 (is_marker_for) | |
| Disease | congenital heart disease (is_implicated_in) | 2.09e-06 | 24 | 31 | 3 | DOID:1682 (is_implicated_in) | |
| Disease | thyroid hormone resistance syndrome (implicated_via_orthology) | 3.20e-06 | 3 | 31 | 2 | DOID:11633 (implicated_via_orthology) | |
| Disease | lung adenocarcinoma (biomarker_via_orthology) | 6.40e-06 | 4 | 31 | 2 | DOID:3910 (biomarker_via_orthology) | |
| Disease | Neoplasm of uncertain or unknown behavior of breast | 1.09e-05 | 41 | 31 | 3 | C0496956 | |
| Disease | Breast adenocarcinoma | 1.09e-05 | 41 | 31 | 3 | C0858252 | |
| Disease | Bladder Neoplasm | 1.38e-05 | 140 | 31 | 4 | C0005695 | |
| Disease | Malignant neoplasm of urinary bladder | 1.42e-05 | 141 | 31 | 4 | C0005684 | |
| Disease | prostate cancer (is_marker_for) | 2.12e-05 | 156 | 31 | 4 | DOID:10283 (is_marker_for) | |
| Disease | Congenital Abnormality | 5.84e-05 | 11 | 31 | 2 | C0000768 | |
| Disease | Obesity | 6.15e-05 | 205 | 31 | 4 | C0028754 | |
| Disease | obesity (implicated_via_orthology) | 7.39e-05 | 215 | 31 | 4 | DOID:9970 (implicated_via_orthology) | |
| Disease | Malignant neoplasm of breast | 1.01e-04 | 1074 | 31 | 7 | C0006142 | |
| Disease | hepatoblastoma (is_marker_for) | 1.11e-04 | 15 | 31 | 2 | DOID:687 (is_marker_for) | |
| Disease | Uterine leiomyoma, estrogen-receptor positive breast cancer | 1.62e-04 | 18 | 31 | 2 | EFO_1000649, HP_0000131 | |
| Disease | BRCAX breast cancer | 2.01e-04 | 20 | 31 | 2 | EFO_0009443 | |
| Disease | Mammary Carcinoma, Human | 2.03e-04 | 525 | 31 | 5 | C4704874 | |
| Disease | Mammary Neoplasms, Human | 2.03e-04 | 525 | 31 | 5 | C1257931 | |
| Disease | Mammary Neoplasms | 2.06e-04 | 527 | 31 | 5 | C1458155 | |
| Disease | Breast Carcinoma | 2.27e-04 | 538 | 31 | 5 | C0678222 | |
| Disease | Cerebral Astrocytoma | 3.16e-04 | 25 | 31 | 2 | C0750935 | |
| Disease | Intracranial Astrocytoma | 3.16e-04 | 25 | 31 | 2 | C0750936 | |
| Disease | Pilocytic Astrocytoma | 3.16e-04 | 25 | 31 | 2 | C0334583 | |
| Disease | Astrocytoma | 3.16e-04 | 25 | 31 | 2 | C0004114 | |
| Disease | Juvenile Pilocytic Astrocytoma | 3.16e-04 | 25 | 31 | 2 | C0280783 | |
| Disease | Diffuse Astrocytoma | 3.16e-04 | 25 | 31 | 2 | C0280785 | |
| Disease | Grade I Astrocytoma | 3.16e-04 | 25 | 31 | 2 | C1704230 | |
| Disease | Subependymal Giant Cell Astrocytoma | 3.16e-04 | 25 | 31 | 2 | C0205768 | |
| Disease | Mixed oligoastrocytoma | 3.16e-04 | 25 | 31 | 2 | C0547065 | |
| Disease | Childhood Cerebral Astrocytoma | 3.16e-04 | 25 | 31 | 2 | C0338070 | |
| Disease | Gemistocytic astrocytoma | 3.42e-04 | 26 | 31 | 2 | C0334581 | |
| Disease | Protoplasmic astrocytoma | 3.42e-04 | 26 | 31 | 2 | C0334580 | |
| Disease | Fibrillary Astrocytoma | 3.42e-04 | 26 | 31 | 2 | C0334582 | |
| Disease | Anaplastic astrocytoma | 3.69e-04 | 27 | 31 | 2 | C0334579 | |
| Disease | lung non-small cell carcinoma (is_implicated_in) | 4.17e-04 | 139 | 31 | 3 | DOID:3908 (is_implicated_in) | |
| Disease | suicidal ideation | 4.26e-04 | 29 | 31 | 2 | EFO_0004320 | |
| Disease | Mammary Neoplasms, Experimental | 5.74e-04 | 155 | 31 | 3 | C0024668 | |
| Disease | breast cancer, ovarian carcinoma | 6.95e-04 | 37 | 31 | 2 | EFO_0001075, MONDO_0007254 | |
| Disease | systemic lupus erythematosus (implicated_via_orthology) | 9.39e-04 | 43 | 31 | 2 | DOID:9074 (implicated_via_orthology) | |
| Disease | breast cancer (is_marker_for) | 9.58e-04 | 185 | 31 | 3 | DOID:1612 (is_marker_for) |
| Peptide | Gene | Start | Entry |
|---|---|---|---|
| QQQQVLSILHANPQL | 2066 | Q09472 | |
| ITPAHFQLLRQQQQQ | 2746 | Q96L91 | |
| VLQQLLVLQPEQQLN | 426 | Q92903 | |
| ANVPQIRQRVHQILN | 506 | Q8WYA6 | |
| LRLQFQVLVQHPQNE | 326 | Q9H5V8 | |
| VPQLQQQVQVLSQIQ | 2561 | Q12830 | |
| RTVTELILQHQNPQQ | 161 | Q9HBD1 | |
| VTELILQHQNPQQLS | 166 | Q5TC82 | |
| QPHLVQTQQVQPQNL | 2376 | P46531 | |
| RQISDPIQQILIQLH | 1026 | Q6ZWH5 | |
| TLQQQHQRLAQLLLI | 496 | P03372 | |
| LQQQVLSPQQLQVLL | 116 | Q9H334 | |
| LQQPQHIQLQVVQVA | 936 | Q9NQV6 | |
| LTQLHPRHQRILQQQ | 151 | C9JE40 | |
| IQLLQQQQQQLPFHP | 486 | O75460 | |
| QVLNQQNIPQISIVV | 121 | Q14993 | |
| LQSQIHVQRIPISNV | 191 | Q96LA5 | |
| NLEHLRQQLLEQQQP | 311 | Q9UPN6 | |
| LQQQQIHQLQLIEQI | 236 | Q9NSC2 | |
| HPLEILQAQIQLQRQ | 1151 | Q10571 | |
| LQNVQLQAVNPTQVL | 441 | Q02446 | |
| QQQPQHIQLQTQQLR | 751 | Q3ZLR7 | |
| HIQLQTQQLRVLQQP | 756 | Q3ZLR7 | |
| TQQLRVLQQPQHIQL | 761 | Q3ZLR7 | |
| VLQQPQHIQLQTQQL | 766 | Q3ZLR7 | |
| QHIQLQTQQLRVLQQ | 771 | Q3ZLR7 | |
| LQLQQRLQGQQQLIH | 1056 | Q15788 | |
| QENLRQHILQQVLQL | 126 | Q8N8I0 | |
| LVQNQPNQLRLQLQH | 1181 | Q15596 | |
| PNQLRLQLQHRLQAQ | 1186 | Q15596 | |
| LQLQHRLQAQQNRQP | 1191 | Q15596 | |
| QQVVQIPQQALRVVQ | 311 | Q02086 | |
| QQQLQQRQILLGPNT | 111 | Q9NS69 | |
| IQQQNPELIEQLRNH | 276 | Q96EQ0 | |
| HVVQGPQVRQLEQQL | 406 | P10827 | |
| HQQILPQQQQNQLSI | 1846 | Q15911 | |
| RLIQQRLLHQQQPLH | 26 | P22033 |